EP0971952A2 - Diagnoseverfahren und reagenzien - Google Patents

Diagnoseverfahren und reagenzien

Info

Publication number
EP0971952A2
EP0971952A2 EP98917502A EP98917502A EP0971952A2 EP 0971952 A2 EP0971952 A2 EP 0971952A2 EP 98917502 A EP98917502 A EP 98917502A EP 98917502 A EP98917502 A EP 98917502A EP 0971952 A2 EP0971952 A2 EP 0971952A2
Authority
EP
European Patent Office
Prior art keywords
disease
protein
mutant
rna
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98917502A
Other languages
English (en)
French (fr)
Inventor
Frederik W. Van Leeuwen
Franklin G. Grosveld
Johannes Peter Henri Burbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erasmus Universiteit Rotterdam
Koninklijke Nederlandse Akademie van Wetenschappen
Universiteit Utrecht
Original Assignee
Erasmus Universiteit Rotterdam
Rijksuniversiteit Utrecht
Koninklijke Nederlandse Akademie van Wetenschappen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erasmus Universiteit Rotterdam, Rijksuniversiteit Utrecht, Koninklijke Nederlandse Akademie van Wetenschappen filed Critical Erasmus Universiteit Rotterdam
Publication of EP0971952A2 publication Critical patent/EP0971952A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the invention encompasses methods and reagents for the diagnosis of a disease caused by or associated with a transcript mutation giving rise to a frameshift mutation within an RNA molecule.
  • the methods include the steps of providing a body fluid or tissue sample from a patient; and analyzing the sample for the presence of an RNA molecule having a frameshift mutation or a protein encoded thereby, wherein the presence of the mutated RNA or encoded protein is indicative of the disease. It is an object of the present invention to provide methods and assays for detection and/or treatment of diseases involving transcript mutations, particularly those diseases relating to aging, wherein the probability of having the disease increases with the age of the patient.
  • the invention contemplates detection and/or treatment of those age-related diseases which are due to mutations occurring in the RNA of cells. If the mutations are not corrected, the disease may result.
  • Another object of the invention is to treat diseases identified according to the invention, by providing to a patient afflicted with the disease or having a propensity to develop the disease, a corrective agent such as an enzyme or oligonucleotide.
  • Yet another object of the invention is to provide a method for identifying age-related diseases by correlating nucleotide sequence mutation hotspots with the disease.
  • Other objects of the invention relate to identification, detection and treatment of age-related diseases including cancers (especially non-hereditary cancers) and neurodegenerative diseases, such as Alzheimer's Disease (AD), Downs' syndrome, 5 frontal lobe dementia (Pick's Disease), progressive supranuclear palsy (PSP) and other diseases with abundant tau-positive filamentous lesions (such as Corticobasal degeneration, Dementia pugilistica, Dementia with tangles only, Dementia with tangles and calcification, Frontotemporal dementias with Parkinsonism linked to chromosome 17, Gertsmann-Strassler-Scheinker disease with tangles, Myotonic o dystrophy, Niemann-Pick disease type C, Parkinsonism-dementia complex of Guam, Postencephalitic Parkinsonism and Subacute sclerosing panencephalitis), Parkinson's
  • AD Alzheimer's Disease
  • Pick's Disease 5 frontal lobe dementia
  • PD Alzheimer's disease
  • amyotrophic lateral sclerosis Huntington's Disease
  • multiple sclerosis dementia with Lewy bodies, multisystem atrophy
  • other inclusion body diseases associated with ubiquitin such as Alexander's disease, Alcoholic liver disease, lichen amyloidosis, and during aging Marinesco bodies and Hyaline inclusions
  • diabetes mellitus type II and other degenerative diseases, such as cardiovascular diseases and rheumatoid arthritis.
  • Early disease diagnosis is imporfant for effective treatment.
  • AD Alzheimer's Disease is in most cases a disease which is related to aging. AD is characterized by atrophy of nerve cells in the cerebral cortex, subcortical areas, and hippocampus and the presence of plaques, dystrophic neurites, neuropil threads and neurofibrillary tangles. In most cases, it is not known whether AD is caused by a genetic abnormality or by environmental factors, or both. The pathogenic mutation is unknown.
  • Another object of the invention is to provide a diagnostic test for AD which enables definitive diagnosis of AD in living patients. Furthermore, as AD is a progressive disease, it is desirable to diagnose AD as early as possible so that preventative action may be taken.
  • Another object of the invention is to provide for detection of AD preferably early on in the disease state. It is desirable to detect a protein or substance which is either directly responsible for the disease or is involved early on in the pathogenesis of the disease, or if not involved is nevertheless generated directly or indirectly by the mechanism causing the disease. Such a protein or substance may be the "causative" agent to the disease or may be "associated with" the disease state in the sense of being diagnostic of the disease state.
  • a missense mutation involves a nucleotide substitution, usually a single nucleotide substitution, which results in an amino acid substitution at the corresponding codon.
  • the missense mutations disclosed in Sherrington et al. are predicted to change the encoded amino acid at the following positions (numbering from the first putative initiation codon) Met to Leu at codon 146, His to Arg at codon 163, Ala to Glu at codon 246, Leu to Val at codon 286, Cys to Tyr at codon 410.
  • AD Alzheimer's disease
  • the present invention is based on the observation that an RNA molecule containing a frameshift mutation and encoding a corresponding mutant protein are o correlated with the presence of a disease.
  • a method for the diagnosis of a disease caused by or associated with an RNA molecule having one or more mutations giving rise to a frameshift mutation comprising: i. providing a biological sample, such as a body fluid or tissue sample, from a patient; and ii. 5 analyzing the sample for the presence of an RNA molecule having a frameshift mutation or a mutant protein encoded thereby, wherein the presence of the mutated RNA or mutant protein is indicative of the disease.
  • a “mutant" protein is a polypeptide encoded by a mutant mRNA at least a part of which is in a reading frame that is shifted relative to the initiation start codon o from that of the native or wild-type reading frame, and thus will include any protein having an aberrant carboxy terminal portion which is encoded by the +1 or +2 reading frame of the wild type gene sequence.
  • the mutant protein will include a hybrid wild-type/nonsense protein having an amino terminal amino acid sequence that is encoded by the wild type (O) reading frame and a carboxy terminal amino acid 5 sequence that is encoded by the +1 or +2 reading frame, and thus the nonsense portion of the mutant protein.
  • the cross-over point between the wild type and nonsense amino acid sequences is the codon containing the frameshift mutation.
  • the invention is based on the discovery of the presence of such a mutant protein or an accumulation of more than one mutant protein in a tissue from a diseased o individual, and also on identification of the mutant protein as indicative of the disease.
  • the invention is also based on the discovery that the mutation that gives rise to the mutant protein occurs at the RNA level and not at the DNA level.
  • RNA molecule which is either fully or partly responsible for the disease, or an RNA molecule which is not responsible for the disease but is associated with the diseased state in the sense that it is diagnostic of the diseased state.
  • a disease caused by or associated with at least one RNA molecule having one or more mutations giving rise to a frameshift mutation can be any disease including non-hereditary cancers, neurodegenerative diseases such as Alzheimer's Disease (AD); Downs' syndrome; frontal lobe dementia (Pick's Disease); progressive supranuclear palsy (PSP) and other diseases with abundant tau-positive filamentous lesions such as Corticobasal degeneration, Dementia pugilistica, Dementia with tangles only, Dementia with tangles and calcification, Frontotemporal dementias with Parkinsonism linked to chromosome 17, Gertsmann-Strassler-Scheinker disease with tangles, Myotonic dystrophy, Niemann-Pick disease type C, Parkinsonism-dementia complex of Guam, Postencephalitic Parkinsonism and Subacute sclerosing panencephalitis; Parkinson's Disease (PD) amyotrophic lateral sclerosis; Huntington's
  • Hyaline inclusions and other degenerative diseases such as cardiovascular diseases, rheumatoid arthritis and Diabetes mellitus type II.
  • Cancers treatable according to the invention include, but are not limited to, Hodgkin's disease, acute and chronic lymphocytic leukemias, multiple myeloma, breast, ovary, lung, and stomach or bladder cancers.
  • RNA molecule having a transcript mutation which leads to a frameshift mutation can be any RNA molecule having at least one transcript mutation which leads to a frameshift mutation.
  • the RNA molecule may be any RNA molecule including primary transcripts and messenger RNA (mRNA).
  • mRNA messenger RNA
  • transcription mutation refers to a mutation which occurs at the RNA level but does not occur in the DNA from which the RNA was transcribed. In order to identify transcript mutations a comparison between the RNA and the DNA from which the RNA was transcribed has to be made.
  • a "frameshift mutation” refers to a deletion or insertion of one or more nucleotides within an open reading frame, for example, a single nucleotide or dinucleotide deletion or insertion, such that the reading frame of the coding region is shifted by one or two nucleotides.
  • the frameshift mutation is a nucleotide or dinucleotide deletion leading to a + 1 or +2 frameshift mutation.
  • any number of nucleotide deletions can occur provided a frameshift mutation results.
  • the insertion of one or more nucleotides may give rise to a frameshift and such mutations also form part of the present invention.
  • the mutation is a nucleotide and more preferably a dinucleotide deletion or insertion associated with the nucleotide sequence GAGA or its complementary sequence CTCT of the RNA molecule; especially preferred frameshift mutations are associated with the nucleotide sequence of the RNA comprising GAGAX or CTCTX, where X is one of G, A, U or C, the preferred motifs being GAGAG, GAGAC, GAGAT, and GAGAA as well as CTCTC, CTCTG, CTCTA and CTCTT.
  • GAGA mutation may refer to either a single nucleotide insertion or deletion or a dinucleotide insertion or deletion within the GAGA or CTCT motif itself or adjacent to (5'- or 3'-terminal to-, and within 5-10 nucleotides of-) the GAGA or CTCT motif.
  • the dinucleotide deletion is a GA deletion within the GAGA motif or a GT deletion immediately following (i.e., within 10 nucleotides 3' of) a GAGA motif and a CT deletion in the CTCT motif.
  • the mutant RNA has one or two dinucleotide deletions associated with a GAGA, GAGAC, GAGAG, GAGAT or GAGAA, or with a CTCT, CTCTG, CTCTC, CTCTA or CTCTT, leading to a + 1 or + 2 frameshift mutation respectively.
  • the transcript mutations occur in
  • RNA molecules of the neuronal system where the disease is a neurodegenerative disease.
  • the "neuronal system” is defined as any cells, RNA molecules, proteins or substances relating to or forming part of the neuronal system such as nerve cells, glial cells, proteins including Tau, ⁇ amyloid precursor protein, ubiquitin B, apolipoprotein E4, neurofilament proteins and microtubule associated protein II, presenilin I, presenilin II, Big Tau, glial fibrillary acidic protein (GFAP), Human P53 cellular tumor antigen, human B-cell leukemia/lymphoma 2 (BCL-2) protooncogene, semaphorins human homolog of yeast up-frameshift protein 1 (HUPF-I), Human Motility Group Protein (HMG), neuron specific protein A (NSP-A) and the RNA molecules encoding the proteins.
  • a neuronal system such as nerve cells, glial cells, proteins including Tau, ⁇ amyloid precursor protein, ubiquitin B, apolipoprotein E4, neurofilament proteins and microtubule associated
  • the preferred mutant RNA molecules of the present invention are those encoding the ⁇ amyloid precursor protein, the Tau protein, ubiquitin, apolipoprotein-E 4 (Apo-E 4 ), microtubule associated protein II (MAP 2), the neurofilament proteins, presenilin I, presenilin ll, Big Tau, GFAP, P53, BCL2, HUPF-I, HMG and NSP-A, having a deletion, insertion or other modification leading to a frameshift mutation.
  • the ⁇ amyloid precursor protein the Tau protein, ubiquitin, apolipoprotein-E 4 (Apo-E 4 ), microtubule associated protein II (MAP 2)
  • the neurofilament proteins presenilin I, presenilin ll, Big Tau, GFAP, P53, BCL2, HUPF-I, HMG and NSP-A, having a deletion, insertion or other modification leading to a frameshift mutation.
  • RNA molecules of the present invention are those encoding ⁇ amyloid precursor protein, ubiquitin B, MAP 2, the neurofilament proteins, presenilin 5 I, presenilin II, Big Tau, GFAP, P53, bcl2 and HUPF-I, which have a frameshift mutation.
  • the mutation is a GA or a GT dinucleotide deletion associated with (within or within 10 nucleotides 5' or 3' of) a GAGA or GAGAX sequence leading to a frameshift mutation or a CT or CA dinucleotide deletion o associated with (within or within 10 nucleotides 5' or 3' of) a CTCT or CTCTX sequence leading to a frameshift mutation.
  • the mutant RNA molecule has one or two GA or GT deletions or one or two CT or CA deletions, each associated with a GAGA or CTCT sequence or similar motif, leading to a + 1 or + 2 frameshift mutation, respectively.
  • mutant protein as used herein is defined as the protein encoded by the mutant RNA molecule of the present invention.
  • the methods of the present invention are for the diagnosis of a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation.
  • a preferred disease for diagnosis by the present invention is AD, except the early onset AD cases found to be linked to chromosome 1, 14 and 21. It is further preferred that the methods of the present invention are for the diagnosis of young and late onset AD, especially non- familial or "sporadic" late onset AD cases.
  • biological sample refers to a body fluid or body tissue which contains proteins and/or cells from which nucleic acids and proteins can be isolated.
  • Preferred sources include buccal swabs, blood, sperm, epithelial or other tissue, milk, urine, cerebrospinal fluid, sputum, fecal matter, lung aspirates, throat swabs, genital swabs and exudates, rectal swabs, and nasopharyngeal aspirates.
  • the body fluid sample can be any body fluid which contains cells having the transcript mutation which gives rise to the frameshift mutation and causes or is associated with the diseases.
  • the body fluid sample contains cells of the neuronal system or the products of such cells.
  • the preferred body fluid is cerebral spinal fluid, which can be obtained after a lumbar puncture 5 (Lannfelt et al, Nature Medicine, 1, pp 829-832, 1995).
  • Another preferred body fluid is blood (including, but not limited to, venous, arterial and cord blood), as it is easily obtained and contains lymphocytes which can be analyzed for the presence of the mutant RNA molecule or encoded protein.
  • the tissue sample can be any tissue and is preferably one that can be easily o obtained, such as skin and nose epithelium.
  • a nucleic acid probe is used.
  • the nucleic acid probe is preferably a nucleotide probe having a sequence complementary to part of the mutant RNA molecule encompassing the mutation giving rise to the frameshift mutation. The probe must be used to detect RNA or DNA reverse transcribed from the
  • RNA but must not be used to detect genomic DNA as the genomic DNA will not contain the mutation.
  • the present invention further provides a nucleic acid probe having a sequence complementary to part of the mutant RNA molecule encompassing the mutation leading to the frameshift mutation.
  • the probe is preferably sufficiently complementary to the mutant sequence of the RNA molecule so that under stringent conditions the probe only remains bound to the mutant sequence, and is able to distinguish under stringent conditions the mutant and corresponding wild-type transcripts.
  • Stringent conditions are defined herein as RNA.DNA hybridization conditions which may be performed at 65 °C using a hybridization buffer equivalent to 50% formamide and 0.1X SSC (see below and Evans et al. PNAS (1994) 9; 6059- 6063, 6060).
  • “Stringent” conditions also preferably include stringent washes, as described in Evans et al. (Ibid).
  • the probe may be of any length but is preferably between 5 and 50 nucleotides long, more preferably between 10 and 30 nucleotides long.
  • the probe may be 5, 10, 15, 20, 25, or 30 nucleotides in length.
  • the probe comprises a sequence complementary to a GAGA or GAGAX or to a CTCT or CTCTX, having a nucleotide or dinucleotide deletion or insertion, and nucleotide sequences corresponding to the nucleotide sequences flanking the GAGA or CTCT motif in the wild-type RNA molecule. It would be apparent to one skilled in the art that if reverse transcribed DNA complementary to the mutant RNA sequence was being probed for, a probe comprising a sequence complementary to the corresponding GAGA or CTCT motif present in the complementary DNA would have to be used.
  • Methods of detecting the presence of the mutant RNA molecule include the reverse transcriptase polymerase chain reaction (RT-PCR) using primers having a sequence complementary to the sequence either side of the mutation which gives rise to the frameshift mutation. Firstly, one primer is used to reverse transcribe the RNA into DNA, and secondly, two primers are used to amplify the DNA, as described hereinbelow.
  • RT-PCR reverse transcriptase polymerase chain reaction
  • the primers used in the above RT-PCR based method can vary in size from 20bp to 2-3 kb; for example, 20bp, 50bp, lOObp, 50 ⁇ b * p, lOOObp, 1500bp, 2000bp, or 3000bp.
  • the primers can be prepared by a number of standard techniques including cloning the sequences flanking the nucleotide region to be amplified or by synthesizing the primers using phosphoramidite method.
  • the present invention further provides primers for use in the above defined RT-PCR based methods for the amplification of the nucleotide region containing the mutation.
  • an immunological test is employed.
  • the immunological test is preferably based on the use an antibody molecule having specificity for the mutant protein of the present invention and not the wild-type protein.
  • the present invention thus further provides an antibody molecule having specificity for the mutated protein of the present invention but not for the wild-type protein.
  • the antibody is specific for the carboxy terminal end of the mutant protein.
  • the present invention further provides a method for the diagnosis of a neurodegenerative disease or other age-related diseases, or a method for the diagnosis of a person with a susceptibility for these diseases comprising: i. providing a body fluid or tissue sample from a patient; and ii. analyzing the sample for the presence of an RNA molecule of the neuronal system having a frameshift mutation or a protein encoded thereby, wherein the presence of the mutated RNA molecule is indicative of a neurodegenerative disease.
  • the neurodegenerative disease is AD and Downs' syndrome.
  • the present invention also relates to methods for preventing and/or treating the diseases, vectors for preventing and/or treating the diseases and for the production of diagnostic reagents, compositions for preventing and/or treating the diseases, nucleic acid sequences, probes and antibody molecules for use in the present invention and transgenic animals.
  • Therapies contemplated according to the invention include providing to a cell containing a mutant transcript a ribozyme which is capable of selectively eliminating (i.e., cleaving) the mutant transcript, thus rendering the transcript untranslatable.
  • the therapies also may include providing to a cell which is thus treated with a ribozyme a corresponding wild-type transcript which is substantially uncleavable by the ribozyme.
  • the wild-type transcript may contain the wild-type sequence corresponding to the mutant RNA sequence, except for the GAGA or CTCT permutation, and encoding the wild-type protein, and also may include third base (in a codon) silent mutations which further differentiate the wild-type RNA from the mutant RNA sequence, and thus further distinguish the sequences with respect to ribozyme recognition and cleavage.
  • Therapies encompassed by the invention also include providing to cells containing a mutant RNA, an RNA or DNA that is complementary to the mutant RNA and able to form a duplex with the mutant RNA that is untranslatable in the cell.
  • the complementary sequence may be the entire length of the mutant RNA, but is preferably a shorter length, for example, 10, 20, 50 or 100 nucleotides in length.
  • the complementary sequence thus may be administered in the form of an oligonucleotide or may be encoded by an expressible sequence contained in a vector, wherein the vector is administered to the cell.
  • the invention therefore encompasses a pharmaceutical composition 5 comprising a ribozyme that selectively cleaves a target RNA having a GAGA or
  • CTCT mutation admixed with a pharmaceutically acceptable carrier.
  • the invention also encompasses a pharmaceutical composition comprising a ribozyme that selectively cleaves a target RNA having a GAGA or CTCT mutation and a wild-type analog of an RNA having a GAGA or CTCT sequence giving rise to a o frameshift mutation admixed with a pharmaceutically acceptable carrier.
  • a pharmaceutical composition comprising a wild-type analog of an RNA having a GAGA or CTCT sequence giving rise to a frameshift mutation admixed with a pharmaceutically acceptable carrier.
  • the invention also encompasses a pharmaceutical composition wherein the wild-type analog of an RNA comprises a nucleotide sequence having third base silent mutations.
  • the invention also encompasses a pharmaceutical composition
  • a pharmaceutical composition comprising a single stranded nucleic acid having a sequence that is complementary to an RNA having one or more GAGA or CTCT mutations giving rise to a frameshift mutation admixed with a pharmaceutically acceptable carrier.
  • the invention also encompasses a pharmaceutical composition comprising the wild-type analog of a mutant protein in admixture with a pharmaceutically acceptable carrier.
  • the invention also encompasses a vector comprising an expressible gene s encoding a ribozyme that selectively cleaves a target RNA having a GAGA or CTCT sequence.
  • the invention also encompasses a vector comprising an expressible gene encoding a sequence complementary to an RNA having a GAGA or CTCT mutation giving rise to a frameshift mutation. o
  • the invention also encompasses a host cell containing a vector as described herein. -
  • the invention also encompasses a method of treatment and/or prevention of a disease caused by or associated with an RNA having a GAGA or CTCT mutation giving rise to a frameshift mutation, comprising administering the compositions, 5 vectors, or the host cells described above to a patient suffering from or susceptible to the disease.
  • the invention also encompasses the use of a vector encoding a ribozyme that selectively cleaves a target RNA having a GAGA or CTCT mutation under the control of a promoter in therapy. o The invention also encompasses the use of a vector encoding a ribozyme under the control of a promoter in the manufacture of a composition for the treatment of a disease caused by or associated with at least one an RNA having one or more GAGA or CTCT mutations giving rise to a frameshift mutation.
  • the invention also encompasses the use of a vector encoding the sequence complementary to an RNA having one or more GAGA or CTCT mutations giving rise to a frameshift mutation under the control of a promoter in therapy.
  • the invention also encompasses the use of more than one of the compositions, the vectors, or the host cells described above in any combination in therapy.
  • the invention also encompasses the use of more than one of the compositions, the vectors, or the host cells described herein in any combination in the treatment and/or prevention of a disease caused by or associated with at least one an RNA having one or more GAGA or CTCT mutations giving rise to a frameshift mutation.
  • the present invention further provides an early marker for a neurodegenerative disease.
  • the invention provides a diagnostic kit for diagnosing a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation comprising: i. a nucleic acid probe having a sequence complementary to part of the mutant RNA molecule which encompasses the mutation which leads to the frameshift mutation and packaging materials therefor; and ii. means for detecting the probe bound to the mutant RNA molecule.
  • the present invention further provides a diagnostic kit for diagnosing a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation comprising: i. primers for use in an RT-PCR reaction, the primers having a sequence complementary to the sequence either side of the mutation which gives rise to the frameshift mutation, packaging materials therefor, and reagents necessary for performing an RT-PCR reaction and amplifying the DNA sequence containing the mutation; and ii. means for detecting the o amplified DNA sequence containing the mutation.
  • the present invention further provides a diagnostic kit for diagnosing a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation comprising: i. an antibody molecule having specificity for the mutant protein of the present invention and not the wild-type protein; and ii. means for detecting the antibody molecule bound to the mutant protein.
  • the antibody molecule and the means for detecting the bound antibody molecule are as defined above.
  • the diagnostic kit described above additionally comprising: i. an antibody molecule having specificity for the wild- type protein; and ii. means for detecting the antibody molecule bound to the wild-type protein, as a control for diagnosing a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation.
  • the present invention further provides an RNA molecule having one or more transcript mutations giving rise to a frameshift mutation which causes or is associated with a disease.
  • the invention further provides several (one or more) RNA molecules encoding the same amino acid sequence up to the GAGA or CTCT motif, and thereafter encoding different sequences.
  • one RNA molecule "encoding a frameshifted protein based on, for example, ⁇ -app may contain a mutation at or within the GAGA motif in ex on 9 of the RNA sequence and a second RNA molecule encoding ⁇ -app may contain a mutation at or within the GAGA motif in exon 10 of the sequence.
  • the present invention further provides a mutated protein encoded by the mutated RNA molecule found to be indicative of a disease, the mutant RNA molecule having one or more transcript mutations giving rise to a frameshift mutation.
  • the mutant protein contains an antigenic epitope specific for the diseased state, examples of which are provided in Table 9.
  • the mutated RNA molecule encodes a protein comprising at least part of the sequence designated +1 or +2 in any one of Figures 2 to 19, or an immunologically equivalent fragment thereof.
  • the mutated protein comprises any one of the following individual sequences: RGRTSSKELA [SEQ ID NO: 1]; HGRLAPARHAS [SEQ ID NO: 2]; YADLREDPDRQ [SEQ ID NO: 3]; RQDHHPGSGAQ [SEQ ID NO: 4]; YADLREDPDRQDHHPGSGAQ [SEQ ID NO: 1400]; GGGAQ [SEQ ID NO: 5], GAPRLPPAQAA [SEQ ID NO: 6]; KTRFQRKGPS [SEQ ID NO: 7]; PGNRSMGHE [SEQ ID NO: 8]; EAEGGSRS [SEQ ID NO: 9]; VGAARDSRAA [SEQ ED NO: 10]; HDYPPGGSV [SEQ ID NO: 11]; SIQKFQV [SEQ ID NO: 12]; VEKPGERGGR [SEQ ED NO: 13]; PLFGRGHKRG [SEQ ED NO: 14];
  • the antibody molecule of the present invention has affinity for the mutant proteins defined above.
  • the present invention also relates to a method for treating and/or preventing a disease caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation.
  • the finding of mutations in RNA molecules which lead to the production of mutant proteins, and which are indicative of a disease, has led to a number of ways of treating and or preventing the disease.
  • the present invention further provides a method for identifying diseases caused by or associated with at least one RNA molecule having one or more transcript mutations giving rise to a frameshift mutation. The method comprises: i. providing the sequence of an RNA molecule suspected of being involved in the pathogenesis of a disease; ii.
  • RNA o sequence 3'-terminal to a frameshift mutation identifying the sequence of the mutant protein encoded by the RNA o sequence 3'-terminal to a frameshift mutation; iii. preparing a probe to the mutant protein or a fragment thereof; and iv. probing a body fluid or tissue sample from a patient having the disease and a patient not having the disease, in order to find a correlation between the presence of the mutant protein and the diseased state.
  • the probe is an antibody molecule as defined herein. It is further preferred that the antibody molecule has affinity for a protein comprising at least one of the sequences: RGRTSSKELA [SEQ ED NO: 1]; HGRLAPARHAS [SEQ ID NO: 2]; YADLREDPDRQ [SEQ ID NO: 3]; RQDHHPGSGAQ [SEQ ED NO: 4]; YADLREDPDRQDHHPGSGAQ [SEQ ED NO: 1400]; GGGAQ [SEQ ED NO: 5], GAPRLPPAQAA [SEQ ED NO: 6]; KTRFQRKGPS [SEQ ID NO: 7]; PGNRSMGHE [SEQ ro NO: 8]; EAEGGSRS [SEQ ID NO: 9]; VGAARDSRAA [SEQ ID NO: 10]; HDYPPGGSV [SEQ ID NO: 11]; SIQKFQV [SEQ ID NO: 12]; VEKPGERGGR [SEQ ID NO
  • Figure 1 is a copy of a paraffin section of the frontal cortex of a female
  • FIG. 1 presents the coding nucleotide sequence of the human ⁇ amyloid precursor protein gene transcript [SEQ ED NO: 25], the amino acid sequence of the wild-type protein [SEQ ID NO: 83 and 84], the mutant + 1 frameshift protein [SEQ ID NO: 50-82] and the mutant + 2 frameshift protein [SEQ ID NO: 26-49].
  • Figure 3 presents the coding nucleotide sequence of the human microtubule- associated protein tau gene transcript [SEQ ID NO: 85], the amino acid sequence of the wild-type protein [SEQ ID NO: 99], the mutant + 1 frameshift protein [SEQ ID NO: 86-98] and the mutant + 2 frameshift protein [SEQ ID NO: 100-112].
  • Figure 4 presents the coding nucleotide sequence of the human ubiquitin B gene transcript [SEQ ID NO: 113], the amino acid sequence of the wild-type protein [SEQ ID NO: 125 and 126], the mutant + 1 frameshift protein [SEQ ID NO: 114- 124] and the mutant + 2 frameshift protein [SEQ ED NO: 127-136].
  • Figure 5 presents the coding nucleotide sequence of the human apolipoprotein E gene transcript [SEQ ID NO: 137], the amino acid sequence of the wild-type protein [SEQ ID NO: 144-146], the mutant + 1 frameshift protein [SEQ ID NO: 138-143] and the mutant + 2 frameshift protein [SEQ ID NO: 147-152]. Information concerning restriction enzyme sites is also given.
  • Figure 6 presents the coding nucleotide sequence of the human microtubule- associated protein 2 transcript [SEQ ID NO: 153], the amino acid sequence of the wild-type protein [SEQ ID NO: 154-158], the mutant + 1 frameshift protein [SEQ ID NO: 232-347] and the mutant + 2 frameshift protein [SEQ ID NO: 159-231].
  • Figure 7 presents the coding nucleotide sequence of the human neurofilament subunit NF-low transcript [SEQ ID NO: 348], the amino acid sequence of the wild- type protein [SEQ ID NO: 466-513], the mutant + 1 frameshift protein [SEQ ID NO: 413-465] and the mutant + 2 frameshift protein [SEQ ID NO: 349-412].
  • 5 Figure 8 presents the coding nucleotide sequence of the human neurofilament subunit NF-M transcript [SEQ ID NO: 514], the amino acid sequence of the wild-type protein [SEQ ID NO: 515-574], the mutant + 1 frameshift protein [SEQ ID NO: 629- 695] and the mutant + 2 frameshift protein [SEQ ID NO: 575-628].
  • Figure 9 presents the coding nucleotide sequence of the human neurofilament o subunit NF-H gene transcript [SEQ ID NO: 696], the amino acid sequence of the wild-type protein [SEQ ED NO: 697-698], the mutant + 1 frameshift protein [SEQ ID NO: 708-710] and the mutant + 2 frameshift protein [SEQ ID NO: 699-707].
  • Figure 10 presents the coding mRNA nucleotide sequence [SEQ ED NO: 711] and amino acid sequence of presenilin I expressed in the wildtype [SEQ ID NO: 712], +1 [SEQ ID NO: 733-753], and +2 [SEQ ID NO: 713-732] reading frames.
  • Figure 11 presents the coding mRNA nucleotide sequence [SEQ ED NO: 754]and amino acid sequence of presenilin II expressed in the wildtype [SEQ ED NO: 776- 787], +1 [SEQ ED NO: 755-775], and +2 [SEQ ID NO: 788-814] reading frames.
  • Figure 12 presents the coding mRNA nucleotide sequence [SEQ ED NO: 815] and amino acid sequence of Big Tau expressed in the wildtype [SEQ ED NO: 816-818], +1 [SEQ ID NO: 824-834] and +2 [SEQ ro NO: 819-823] reading frames.
  • Figure 13 presents the coding mRNA nucleotide sequence [SEQ ED NO: 835] and amino acid sequence of GFAP expressed in the wildtype [SEQ ID NO: 836- 852], +1 [SEQ ID NO: 883-914], and +2 [SEQ ID NO: 853-882] reading frames.
  • Figure 14 presents the coding mRNA nucleotide sequence [SEQ ID NO:
  • Figure 15 presents the coding mRNA nucleotide sequence [SEQ ID NO: 966] and amino acid sequence of BCL2 expressed in the wildtype [SEQ ID NO: 967- 1015], +1 [SEQ ID NO: 1075-1126] and +2 [SEQ ID NO: 1016-1074] reading frames.
  • Figure 16 presents the coding mRNA nucleotide sequence [SEQ ID NO: 1127] and amino acid sequence of Semaphorin III expressed in the wildtype [SEQ ID NO: 1128-1131], +1 [SEQ ID NO: 1 162-1212] and +2 [SEQ ID NO: 1132-1161] reading frames.
  • Figure 17 presents the coding mRNA nucleotide sequence [SEQ ID NO: 1213] and amino acid sequence of HUPF expressed in the wildtype [SEQ ID NO: 1241-1244], +1 [SEQ ID NO: 1214-1240] and +2 [SEQ ID NO: 1245-128 l]reading frames.
  • Figure 18 presents the coding mRNA nucleotide sequence [SEQ ID NO: 1282] and amino acid sequence of HMG expressed in the wildtype [SEQ ED NO: 1297-1299], +1 [SEQ ED NO: 1289-1296] and +2 [SEQ ID NO: 1283-1288] reading frames.
  • Figure 19 presents the coding mRNA nucleotide sequence [SEQ ED NO: 1300] and amino acid sequence of NSP-A expressed in the wildtype [SEQ ID NO: 1374-1387], +1[SEQ ID NO: 1339-1373], and +2 reading frames [SEQ ID NO: 1301-1338].
  • Figure 20 presents the partial mRNA nucleotide sequence and amino acid sequence of two human neuronal proteins ( ⁇ amyloid precursor protein (exons 9 and 10) and Ubiquitin B (exon 2)) expressed in the wildtype and +1 reading frame.
  • ⁇ amyloid precursor protein exons 9 and 10
  • Ubiquitin B exon 2
  • Figure 21 Two examples of novel restriction sites generated by dinucleotide deletion in transcripts of ⁇ amyloid precursor protein and ubiquitin B (wild-type nucleotide sequences, [SEQ ID NO: 25 and 113]; ⁇ amyloid precursor protein deletion sequences [SEQ ID NO: 1396 and 1397]; ubiquitin deletion sequences [SEQ ED NO: 1398-1399].
  • the present invention is based on the discovery that frameshift mutations occur in a single RNA molecule or number of RNA molecules whose product or products are mutant proteins that are associated with, and indicative of, a disease state.
  • the invention is based on the recognition that the presence of a frameshift mutation 5 results in a new coding sequence for the cell containing the frameshift mutation, and thus a new polypeptide (herein termed a mutant protein) which may be correlated with and thus be indicative of a disease.
  • diagnosis and/or identification of a disease caused by or associated with at least one RNA molecule having one or more o transcript mutations which give rise to a frameshift mutation is accomplished as described herein.
  • methods for preventing and/or treating the diseases, vectors for preventing and/or treating the diseases and for the production of diagnostic reagents, compositions for preventing and/or treating the diseases, nucleic acid sequences, probes and antibody molecules for use in the present invention and transgenic animals are accomplished as described herein.
  • the invention relates to methods for diagnosing diseases caused by or associated with at least one RNA molecule having one or more transcript mutations which give rise to a frameshift mutation.
  • diseases include but are not limited to cancers, Diabetes mellitus type II and neurodegenerative diseases such as Parkinson's Disease (PD), Alzheimer's Disease (AD), frontal lobe dementia (Pick's Disease), o progressive supranuclear palsy (PSP) and other diseases with abundant tau-positive filamentous lesions such as Corticobasal degeneration, Dementia pugilistica, Dementia with tangles only, Dementia with tangles and calcification, Frontotemporal dementias with Parkinsonism linked to chromosome 17, Gertsmann-Strassler-Scheinker disease with tangles, Myotonic dystrophy, Niemann-Pick disease type C, Parkinsonism- 5 dementia complex of Guam, Postencephalitic Parkinsonism, Subacute
  • Somatic mutations can result in a different gene function and have been implicated in diseases associated with aging, such as certain cancers.
  • non-proliferating cells do not undergo important changes at the genomic level.
  • genomic changes are mainly related to cell proliferation (Smith, Mutation Research, 277. pp 139-142, 1992) which for non-proliferating cells such as most neurons ends during early postnatal life (Rakic, Science, 277. pp 1054-1056, 1985).
  • Evans et al., 1994, Proc. Nat. Acad. Sci. 91 :6059 suggested that somatic mutations do occur in genes of the neuronal system, i.e., in post-mitotic neurons.
  • the di/di Brattleboro rat which suffers from severe diabetes insipidus due to the absence of the antidiuretic hormone vasopressin (VP), was the subject of the Evans et al. paper. It had previously been established that the VP hormone was absent in the Brattleboro rat due to a deletion of a single G residue in the second exon of the VP gene, resulting in a mutant VP precursor with an altered C-terminal amino acid sequence. It had also been observed that a small number of neurons in the di/di rat exhibited a heterozygous +/di phenotype and expressed an apparently normal VP gene product. In studying the molecular biology of the di/di rat, Evans et al.
  • transcript mutations are occurring and that such transcript mutations are caused by or associated with a disease.
  • methods of detection have been o unreliable as there will be no mutation in the genomic DNA and the probing of genomic DNA will give a false indication of the absence of the mutation.
  • RNA molecule having one or more transcript mutations occurring at a mutational hotspot and which give rise- to a frameshift mutation is identified and/or diagnosed.
  • the nucleotide sequence of an RNA molecule suspected of being involved in the pathogenesis of a disease is provided, e.g., from published gene sequences or from cloning and sequencing of a suspect RNA molecule.
  • the amino acid sequence encoded by the RNA molecule is then predicted, as are amino acid sequences of encoded mutant proteins. Mutant protein sequences are predicted in +1 and +2 reading frames following a hypothesized frameshift mutation.
  • the location of the frameshift mutation may be hypothesized with respect to certain nucleotide sequence motifs which are suspected of causing frameshift mutations, examples of such motifs present in the RNA molecule including but not limited to those comprising GAGA, for example, GAGAC, GAGAG, GAGAT, and GAGAA, or those comprising CTCT, for example CTCTC, CTCTG, CTCTA and CTCTT.
  • a probe is then prepared that is specific for the mutant protein or an immunogenic fragment thereof (such probes being described hereinabove for detection of proteins or protein fragments).
  • part of the mutant protein will have the same sequence as the wildtype protein and part of the protein will have the sequence of the mutant protein.
  • the mutant protein will terminate when the nucleotide sequence codes for a stop codon (indicated as * in the Figures). Thus, different mutant proteins will be produced depending on where the mutation occurs.
  • AD Alzheimer's Disease
  • U.S.A see Coleman, Neurobiol. of Aging, li, Suppl. 2, pp 577-578, 1994), and an estimated 20 million Alzheimer's patients worldwide.
  • AD diagnosis has been defined (see Reisberg et al., Am. J. Psych. 12, pp 1136-1139, 1982; McKhann et al, Neurology, __4, pp 939-944, 1984).
  • the early symptoms of AD vary but generally include depression, paranoia and anxiety. There is also a slow degeneration of intellectual function and memory. In particular, cognitive dysfunction and specific disturbances of speech (aphasia), motor activity (apraxia), and recognition of perception (agnosia) can occur.
  • AD Alzheimer's disease
  • Neuritic plaques are believed to be composed of degenerating axons (e.g., neuropil -breads), nerve terminals and possibly astrocytic and microglial elements. It is also often found that neuritic plaques have an amyloid protein core.
  • the neurofibrillary tangles comprise normal and paired helical filaments and are believed to consist of several proteins.
  • AD degenerating axons
  • nerve terminals e.g., nerve terminals and possibly astrocytic and microglial elements.
  • neuritic plaques have an amyloid protein core.
  • the neurofibrillary tangles comprise normal and paired helical filaments and are believed to consist of several proteins.
  • There are two major types of AD late onset (>65 years) and early onset ( ⁇ 65 years). Approximately 85% of all AD cases are late onset and only 15% are early onset.
  • Diagnostic methods of the invention will include the detection of nucleic acid sequences, preferably via procedures which involve formation of a nucleic acid duplex between two nucleic acid strands, i.e., a nucleic acid probe and a complementary sequence in the mutant RNA or the DNA reverse transcribed from the mutant RNA isolated from a biological sample, or detection of a protein, preferably a mutant or hybrid wild-type/nonsense protein, as defined herein.
  • RNA is prepared from the biological sample by DNA extraction procedures well-known in the art (see, e.g., Sambrook et al., 1990, A Laboratory Manual for Cloning, Cold Spring Harbor Press, CSH, NY), and may be further purified -if desired, e.g., by electro-elution, prior to analysis.
  • Methods of detecting a mutant RNA molecule from a biological sample include, but are not limited to the following: (1) reverse transcriptase polymerase chain reaction (RT-PCR) followed by sizing gel electrophoresis or hybridization with an allele-specific (or sequence-specific) probe; (2) hybridization of the eluted RNA with a nucleic acid probe that is complementary to the mutated RNA; (3) the ARMS test, in which one primer has a complementary sequence encompassing the mutation which gives rise to the frameshift mutation, and amplification only occurs if the mutated sequence is present; (4) nucleotide sequencing; (5) RNA amplification via RT-PCR and T7 polymerase; and (6) by a dinucleotide deletion in the RNA after RT-PCR a cDNA can be generated with novel restriction sites ( Figure 21).
  • a nucleic acid probe useful according to the invention is preferably sufficiently complementary to the mutant sequence of the RNA molecule so that under stringent conditions the probe only remains bound to the mutant sequence (see Evans et al, Proc. Natl. Acad. Sci. USA, 91 :6059-6063 (1994).
  • the probe is preferably labelled using any of the standard techniques known to those skilled in the art, such as radioactively using 32 P or any other standard isotopes-, or using non-radioactive methods including biotin or DIG labelling.
  • the labelled probe can then be easily detected by methods well known to those skilled in the art.
  • An alternative method for detecting the presence of the mutant RNA molecule is via the reverse transcriptase polymerase chain reaction (RT-PCR).
  • Primers having a sequence complementary to the sequence either side of the mutation which gives rise to the frameshift mutation are used to reverse transcribe the RNA and amplify the reverse transcribed DNA containing the mutation.
  • the mutation in the amplified fragment can then be detected using the probe described above using standard techniques or by sequencing the amplified fragment.
  • the advantages of using the RT-PCR reaction is that less starting material is required and the PCR methods allow quantitative as well as qualitative determinations to be made. Quantitative determinations allow the number of copies of a mutated RNA molecule present in a particular sample to be estimated, and given this information the severity of the diseased state can be estimated.
  • Another alternative method for detecting the presence of the mutant RNA molecule is one in which one primer has a complementary sequence encompassing the mutation which gives rise to the frameshift mutation. Amplification will therefore only occur if the mutated sequence is present.
  • RNA is reverse transcribed and the DNA then amplified, e.g., using PCR, prior to analysis.
  • Specific conditions for any one PCR i.e. a PCR targeting a particular sequence, or for any one multiplex
  • PCR i.e. a PCR targeting a particular set of sequences
  • Amplification of a mutated or wild-type reverse transcribed DNA sequence can be accomplished directly from an aliquot of the prepared DNA as follows.
  • a 50 ⁇ l master mix comprises 20 mM Tris HCl, pH 8.3, 100 mM KC1, 5 mM MgCl 2 , 0.02 ⁇ moles each of dATP, dGTP, dCTP, 0.04 ⁇ moles of dUTP, 20 pmoles of each primer (Perkin Elmer Cetus,
  • a fragment characteristic of the selected amplification sequence can then be visualized under ultraviolet light after ethidium bromide staining a 13% polyacrylamide gel in which an aliquot of the amplification has been electrophoresed.
  • hybridization with allele-specific probes can identify the presence of amplified product from either the normal and/or mutant alleles.
  • the sample or eluate may first be treated to release or remove the nucleic acid by mechanical disruption (such as freeze/thaw, abrasion, sonication), physical/chemical disruption, such as treatment with detergents (e.g., Triton, Tween, or sodium dodecylsulfate), osmotic shock, heat, enzymatic lysis (lysozyme, proteinase K, pepsin, etc.), or nuclease treatment, all according to conventional methods well known in the art.
  • mechanical disruption such as freeze/thaw, abrasion, sonication
  • physical/chemical disruption such as treatment with detergents (e.g., Triton, Tween, or sodium dodecylsulfate), osmotic shock, heat, enzymatic lysis (lysozyme, proteinase K, pepsin, etc.), or nuclease treatment, all according to conventional methods well known in the art.
  • detergents e.
  • a biological sample includes a mutant protein, the presence or absence of which is indicative of a genetic disease
  • the protein may be detected using
  • any of the antibody reagents useful in the method of the present invention may comprise whole antibodies, antibody fragments, polyfunctional antibody aggregates, or in general any substance comprising one or more specific binding sites from an antibody.
  • the antibody fragments may be fragments such as Fv, Fab and F(ab') 2 fragments or any derivatives thereof, such as a single chain Fv fragments.
  • the antibodies or antibody fragments may be non-recombinant, recombinant or humanized.
  • the antibody may be of any immunoglobulin isotype, e.g., IgG, IgM, and so forth.
  • aggregates, polymers, derivatives and conjugates of immunoglobulins or their fragments can be used where appropriate.
  • the immunoglobulin source for an antibody reagent can be obtained in any manner such as by preparation of a conventional polyclonal antiserum or by preparation of a monoclonal or a chimeric antibody.
  • Antiserum can be obtained by well-established techniques involving immunization of an animal, such as a mouse, o rabbit, guinea pig or goat, with an appropriate immunogen.
  • the peptide or polypeptide may be conjugated to a conventional carrier (e.g. 5 thyroglobulin) in order to increases its immunogenicity, and antisera to the peptide- carrier conjugate is raised in rabbits.
  • a conventional carrier e.g. 5 thyroglobulin
  • Coupling of a peptide to a carrier protein and immunizations are performed as described (Dymecki, S.M., et al., J. Biol. Chem 267:4815-4823, 1992). Rabbit antibodies against this peptide are raised and the sera titered against peptide antigen by ELISA or alternatively by dot or spot blotting o (Boersma and Van Leeuwen, 1994, Jour. Neurosci. Methods 51:317.
  • the antisera may be used in tissue sections.
  • the sera is shown to react strongly with the appropriate peptides by ELISA, following the procedures of Green et al., Cell, 28, 477-487 (1982).
  • the sera exhibiting the highest titer is used in subsequent experiments. 2.
  • monoclonal antibodies of this invention may be prepared using a synthetic peptide, preferably bound to a carrier, as described by Arnheiter et al., Nature, 294, 278-280 (1981).
  • Monoclonal antibodies are typically obtained from hybridoma tissue cultures or from ascites fluid obtained from animals into which the hybridoma tissue was introduced. Nevertheless, monoclonal antibodies may be described as being “raised to” or “induced by” the synthetic peptides or their conjugates.
  • sandwich hybridization techniques may be used, e.g., an o antibody specific for a given protein.
  • an antibody specific for a haptenic group conjugated to the binding protein can be used.
  • Another sandwich detection system useful for detection is the avidin or streptavidin system, where a protein specific for the detectable protein has been modified by addition of biotin.
  • the antibody may be replaced with a non-immunoglobulin protein which has the property of binding to an immunoglobulin molecule, for example Staphylococcal protein A or Streptococcal protein G, which are well-known in the art.
  • the protein may either itself be detectable -labeled or may be detected indirectly by a detectable labeled secondary binding protein, for example, a second antibody specific for the first antibody.
  • a detectable labeled goat-anti- rabbit immunoglobulin antibody would be a second binding protein.
  • the signal generated by the presence of the hybrid wild-type/nonsense protein is amplified by reaction with a specific antibody for that fusion protein (e.g., an anti- ⁇ -galactosidase antibody) which is detectably labeled.
  • a specific antibody for that fusion protein e.g., an anti- ⁇ -galactosidase antibody
  • One of ordinary skill in the art can devise without undue experimentation a number of such possible first and second binding protein systems using conventional methods well-known in the art.
  • mutant proteins can be detected using chromatographic methods such as SDS PAGE, isoelectric focusing, Western blotting, HPLC and capillary electrophoresis.
  • chromatographic methods such as SDS PAGE, isoelectric focusing, Western blotting, HPLC and capillary electrophoresis.
  • the invention provides methods for identifying diseases caused by or associated with at least one RNA molecule having one or more transcript mutations which give rise to a frameshift mutation.
  • RNA molecules suspected of being involved in the pathogenesis of a disease is provided, e.g., from published gene sequences or from cloning and sequencing of a suspect gene.
  • the amino acid sequence encoded by the RNA is then predicted, as are amino acid sequences of encoded mutant proteins. Mutant protein sequences are predicted in +1 and +2 reading frames following a hypothesized frameshift mutation.
  • the location of the frameshift mutation may be hypothesized with respect to certain nucleotide sequence motifs in the RNA molecule, examples of such motifs including, but not limited to, GAGA, for example, GAGAC, GAGAG, GAGAT, and GAGAA, or CTCT, for example CTCTG, CTCTC, CTCTA and CTCTT.
  • GAGA for example, GAGAC, GAGAG, GAGAT, and GAGAA
  • CTCT for example CTCTG, CTCTC, CTCTA and CTCTT.
  • a probe is then prepared that is specific for the mutant protein or an immunogenic fragment thereof (such probes being described hereinabove for detection of proteins or protein fragments).
  • part of the mutant protein will have the same sequence as the wildtype protein and part of the protein will have the sequence of the mutant protein.
  • the mutant protein will terminate when the nucleotide sequence codes for a stop codon (indicated as * in the Figures). Thus, different mutant proteins will be produced depending on where the mutation occurs.
  • the simplest method of probing for the presence of a particular mutant protein is to make an antibody to that protein or an immunogenic portion thereof.
  • An immunogenic fragment may be synthesized corresponding to the C-terminus of the predicted mutant proteins because even if the mutation occurred at another position in the sequence, the probability that the derived mutant protein contains the peptide sequence is increased.
  • two different transcript modifications have occurred (i.e., at two different GAGA motifs) which result in two frameshifted proteins having identical C-terminal sequences.
  • the C-terminal region of a protein is more likely to form an epitope than other regions of the protein.
  • a biological sample from a patient having the disease and a biological sample from a patient not having the disease is probed for the presence or absence of the mutant protein, also as described above.
  • several probes may be prepared and the combination of probes used to probe the tissue sample.
  • the presence of the mutant protein in a biological sample from a patient having the disease and the absence of said mutant protein in a biological sample from a patient not having the disease indicates that the mutant protein is a marker for the disease or susceptibility to the disease.
  • the invention also relates to methods for preventing and/or treating diseases, vectors for preventing and/or treating the diseases, and compositions such as nucleic acid sequences and proteins for preventing and/or treating the diseases, which methods and compositions are useful in gene and protein therapies.
  • the invention includes methods of treatment and or prevention of a disease caused by or associated with an FIN A having a mutation in GAGA or CTCT giving rise to a frameshift mutation in which a ribozyme, a wild-type RNA, or both, an RNA or DNA that is complementary to the mutant RNA and capable of forming a hybrid with the mutant RNA, or a vector comprising a sequence encoding any of these
  • 15 sequences, or the wild-type form of a mutant protein is administered to a patient suffering from or susceptible to the disease.
  • Preferred diseases which are treated according to the invention include but are not limited to cancer or a neurodegenerative disease, especially AD, the preferred mutant RNAs of the present invention are those encoding the ⁇ amyloid precursor
  • Ribozymes useful in treatment according to the present invention are preferably hammerhead ribozymes.
  • a pharmaceutical composition according to the invention will include a therapeutically effective amount of a ribozyme, the wild-type analog of the mutant RNA, or both, or a DNA or RNA that is complementary to the mutant RNA and
  • a therapeutically effective amount is considered that amount which, when administered to a patient, provides a therapeutic benefit to the patient. Such amounts will generally be in the range of 10 ug-100 mg of therapeutic protein kg body weight of the patient, preferably 50 ug-10 mg, and most preferably 100 ug-1 mg.
  • the vector may be of linear or circular configuration and may be adapted for episomal or integrated existence in the host cell, as set out in the extensive body of literature known to those skilled in the art.
  • the vectors may be delivered to cells using viral or non-viral delivery systems. The choice of delivery system will depend on whether the substance is to be delivered to a selected central nervous system or neuronal cell type or generally to these cells.
  • Vectors of the present invention additionally may comprise further control sequences such as enhancers or locus control regions (LCS), in order to lead to more controlled expression of the encoded gene or genes.
  • LCS are described in EP-A- 0332667.
  • the inclusion of a locus control region (LC), is particularly prefe ⁇ ed as it ensures the DNA is inserted in an open state at the site of integration, thereby allowing expression of the gene or genes contained in the vector.
  • the vectors of the present invention have a wide range of applications in ex vivo and in vivo gene therapy.
  • the invention also includes stable cell lines and transgenic animals for use as disease models for testing or treatment.
  • a stable cell line or transgenic animal according to the invention will contain a recombinant gene or genes, also known herein as a transgene, encoding one or more mutations giving rise to a frameshift mutation which causes or is associated with a disease.
  • the recombinant gene will encode an RNA encoding a mutated protein found to be indicative of a disease.
  • the mutant protein will contain an antigenic epitope specific for the diseased state.
  • the recombinant gene may encode a protein comprising at least part of the sequence designated +1 or +2 in any one of Figures 2 to 9, or an immunologically equivalent fragment thereof.
  • a cell line containing a transgene encoding a mutant protein, as described herein, is made by introducing the transgene into a selected cell line according to any one of several procedures known in the art for introducing a foreign gene into a cell.
  • a transgenic animal containing such a transgene includes a rodent, such as a rat or mouse, or other mammals, such as a goat, a cow " , etc. and may be made according to procedures well-known in the art.
  • Transgenic animals are useful according to the invention as disease models for the purposes of research into diseases caused by or associated with at least one gene encoding an RNA containing one or more mutations giving rise to a frameshift mutation, and therapies therefore.
  • therapies including gene therapy and various drugs can be tested on the transgenic animals.
  • Recombinant genes introduced into an animal to make a transgenic animal useful in the invention will include those genes specifically disclosed herein, containing a dinucleotide deletion or insertion relative to the wildtype sequence of the gene, the dinucleotide deletion or insertion being associated with the nucleotide sequence GAGA or CTCT; for example GAGAX or CTCTX, where X is one of G, A,
  • Such transgenes will preferably contain a dinucleotide deletion which is an AG deletion or a GT deletion just adjacent to GAGAG ( Figure 20), for example, one or two dinucleotide deletions associated with a GAGA, GAGAG, GAGAC, GAGAT, GAGAA leading to a + 1 or + 2 frameshift mutation respectively.
  • CTCTX can undergo the same deletion process ( ⁇ CT).
  • Recombinant transgenes containing such a mutation which are particularly useful in animal models of disease include those associated with neurodegenerative diseases, especially Alzheimer's disease, and include but are not limited to mutant gene sequences disclosed herein encoding mutant ⁇ amyloid precursor protein, the Tau protein, ubiquitin B, apolipoprotein-E 4 (Apo-E 4 ), microtubule associated protein ⁇ (MAP 2), the neurofilament proteins (L, M, H), presenilin I, presenilin II, Big Tau, GFAP, P53, BCL2, semaphorin EU, HUPF, HMG and NSP-A (see also Tables 2-8).
  • transgenic animals of the invention may contain transgenes that are controlled via a regulatable and/or a regulated promoter such that the co ⁇ esponding wildtype protein is expressed during selected stages of development and maturity of the animal and in a selected tissue, and the mutant gene is turned-on when desired.
  • a regulatable and/or a regulated promoter such that the co ⁇ esponding wildtype protein is expressed during selected stages of development and maturity of the animal and in a selected tissue, and the mutant gene is turned-on when desired.
  • the mutant gene is under the control of a brain-specific inducible promoter, e.g., a neurofilament, aldolase or modified Thy-1 promoter, then onset of the disease may be controlled via expression of the mutant gene.
  • Transgenic animals according to the invention may be generated to over-express a) human ⁇ amyloid precursor protein +1, b) human ubiquitin +1 proteins, c) human neurofilament proteins.
  • EXAMPLE 1 Described below is an embodiment of the invention involving identification of transcript frameshift mutations in RNA molecules encoding proteins which are present in neuronal tissue, and how such mutations are useful in diagnosis of certain disease states.
  • cDNA sequences coding for the human ⁇ amyloid precursor protein, Tau, ubiquitin, apolipoprotein E4, MAP 2, the neurofilament subunits low, medium and high, presenilin I, presenilin II, Big Tau, GFAP, P53, BCL2, semaphorin III, HUPF-I, HMG and NSP-A were obtained from various gene sequence databases.
  • sequence data the various GAGA or CTCT motifs in the sequences were identified, and deletions were hypothesized and the sequences of the derived mutant proteins predicted, as shown in Figures 2-19. Both the sequences of the +1 and +2 frameshift mutant proteins were predicted.
  • a peptide o co ⁇ esponding to the C-terminus of the hypothesized mutant proteins was synthesized.
  • the peptides were synthesized using standard techniques known to those skilled in the art.
  • RGRTSSKELA SEQ ID NO: 1]; HGRLAPARHAS [SEQ ID NO: 2]; YADLREDPDRQ [SEQ ID NO: 3]; RQDHHPGSGAQ [SEQ ED NO: 4]; YADLREDPDRQDHHPGSGAQ [SEQ ID NO: 1400]; GGGAQ [SEQ ID NO: 5], GAPRLPPAQAA [SEQ ID NO: 6]; KTRFQRKGPS [SEQ ID NO: 7]; PGNRSMGHE [SEQ ID NO: 8]; EAEGGSRS [SEQ ID NO: 9]; VGAARDSRAA [SEQ ID NO: 10]; HDYPPGGSV [SEQ ro NO: 11]; SIQKFQV [SEQ ID NO: 12]; VEKPGERGGR [SEQ ID NO: 13]; PLFGRGHKRG [SEQ ro NO: 14]; EDRGDAGWRGH
  • part of the mutant protein will have the same sequence as the wild-type protein and part of the protein will have the sequence of the mutant protein. Furthermore, depending on where the mutation occurs the mutant protein will terminate when the nucleotide sequence codes for a stop codon (indicated as * in the Figures). Thus different mutant o proteins will be produced depending on where the mutation occurs.
  • Peptides were synthesized co ⁇ esponding to the C-terminus of the predicted mutant proteins because even if the mutation occu ⁇ ed at another position in the 5 sequence the probability that the derived mutant protein contains the peptide sequence is increased. Furthermore, the C-terminus region of a protein is more likely to form an epitope than other regions of the protein.
  • the antibodies obtained were then tested on autopsy material of frontal cortex, temporal lobe and hippocampus of neuropathologically confirmed AD cases and control non- AD cases.
  • the presence of the antibodies is determined using standard detection methods known to those skilled in the art.
  • Figure 1 shows the presence of the ⁇ amyloid precursor mutant protein ( ⁇ APP +1 ) in the frontal cortex of an Alzheimer patient identified using an antibody against a peptide predicted by the +1 reading frame of ⁇ amyloid precursor protein.
  • the antibody used had affinity for a peptide having the following sequence RGRTSSKELA [SEQ ID NO: 1].
  • the presence of the mutant protein can be detected and co ⁇ elates with the subject having AD.
  • the presence of one or more of the mutant proteins can therefore be seen to be indicative of AD.
  • Table 6 summarizes the immunoreactivity results within the frontal cortex (area 11), temporal cortex (area 38) and the hippocampus.
  • Downs' syndrome is trisomy of chromosome 21 which leads to over-expression of ⁇ -amyloid precursor protein.
  • the frontal and temporal cerebral cortex and hippocampus of these patients contained plaques and neurofibrillary tangles, and hypothesized that such over-expression may promote accumulation of transcript mutations in neurons, by frameshift mutations at a GAGAG motif in the over-expressed ⁇ -amyloid gene.
  • the mutant amyloid protein is co ⁇ elated not only with Alzheimer's disease, but also with other diseases, such as Downs', involving Alzheimer's neuropathology.
  • Table 7 shows the presence of the complementary GAGA motifs in various 5 cDNAs ofthe neuronal system.
  • the motif or, as can be seen from the sequences of Tau and apolipoprotein E4, similar motifs such as GAGAG GAGAC, GAGAA, and GAGAT (in the cDNA) may be associated with the frameshift mutations that lead to or are associated with the disease.
  • the presence of the motif or similar motifs in other RNA molecules may indicate that they are relevant to a disease. It is also possible that o other mutations occur that are not associated with such motifs but still lead to frameshift mutations that cause or are associated with a disease.
  • Table 8 shows the presence of GAGAC motifs in particular RNA molecules of the neuronal system, namely ⁇ APP, Tau and Ubiquitin. This table also indicates, inter alia, the chromosomal location of the genes from which the mutant RNA s molecules are transcribed and the molecular weight of the longest polypeptide forms encoded by the RNA molecules and the predicted size of the abe ⁇ ant +1 peptide with its C-terminus against which the antibodies were raised. These peptides were revealed in a Western blot and also identified with a different antibody recognizing an epitope on the unaffected wild-type N-terminus. 0 EXAMPLE 2
  • Synthetic polypeptides co ⁇ esponding in sequence to a portion of a mutant protein will be useful 5 according to the invention as antigenic peptides for generation of antibodies specific for a mutant protein, provided they possess the following characteristics.
  • the synthetic peptide will include a minimum of 8 and preferably 12-15 amino acid residues, and an optimum length of 20-21 amino acids.
  • the hydrophilicity and antigenic index of the amino acid sequence of the hybrid wild-type/nonsense protein 0 may be determined by Analytical Biotechnology Sciences, Boston, MA, using computer programming.
  • Potential synthetic peptides useful according to the invention include a stretch of 12-20 amino acids preferably within the carboxy terminal 100-150 amino acids of the hybrid wild-type/nonsense protein.
  • amino acid sequence of a selected peptide is searched in a computer database of sequences (e.g., GenBank) to preclude the possibility that at reasonable concentrations, antisera to any one peptide would specifically interact with any protein of a known sequence.
  • Prefe ⁇ ed sequences are those which are determined not to have a close homolog (i.e., "close” meaning 80-100% identity).
  • Another embodiment of this invention relates to an assay for the presence of the "mutant" or mutant protein in a given tissue as indicative of a disease state.
  • an above-described antibody is prepared.
  • the antibody or idiotype-containing polyamide portion thereof is then admixed with candidate tissue and an indicating s group.
  • the presence of the naturally occurring amino acid sequence is ascertained by the formation of an immune reaction, as signalled by the indicating group.
  • Candidate tissues include any tissue or cell line or bodily fluid to be tested for the presence of the mutant protein, as described hereinabove.
  • Expression of a given hybrid wild-type/nonsense protein may be investigated o using antiserum prepared in rabbits against a peptide co ⁇ esponding to a carboxy terminal stretch of amino acids in the hybrid wild-type/nonsense protein as follows.
  • CMK cells or U3T3 cells are metabolically labeled with 35 S-methionine and extracts are immunoprecipitated with antiserum. If the hybrid wild-type/nonsense protein is present in the cells, then a protein species of co ⁇ esponding molecular weight 5 will be detected in CMK and U3T3 cells.
  • the protein may be localized to the membrane, nucleus or cytoplasm by Western blot analysis of the nuclear, membrane and cytoplasmic fractions, as generally described in Towbin et al, Proc. Natl. Acad. Sci. USA, 76, 4350-4354 (1979). This localization may be confirmed by immunofluorescence analysis to be associated mainly with the plasma membrane.
  • Relative protein concentrations are determined with a colorimetric assay kit (Bio-Rad) with bovine serum albumin as the standard.
  • a protein of lysate containing approximately 0.05 mg of protein was mixed with an equal volume of 2 x SDS sample buffer containing 2 mercaptoethanol, boiled for 5 min., fractioned on 10% polyacrylamide-SDS gels (Konopka, J.B., et al., J. Virol., 51 :223-232, 1984) and transfe ⁇ ed to immunobilon polyvinyldine difluoride (Millipore Corp., Bedford, MA) filters. Protein blots were treated with specific antipeptide antibodies (see below). Primary binding of the specific antibodies may be detected using anti-IgG second antibodies conjugated to horseradish peroxidase and subsequent chemiluminescence development ECL Western blotting system (Amersham International).
  • CMK cells are resuspended in 1 ml of 5 sonication buffer (60 mM Tris-HCl, pH 7.5; 6 mM EDTA, 15 mM EGTA, 0.75 M sucrose, 0.03% leupeptin 12 mM phenylmethylsulfonyl fluoride, 30 mM 2- mercaptoethanol).
  • Cells are sonicated 6 times for 10 seconds each and centrifuged at 25,000 xg for 10 min at 4°C. The pellet is dissolved in 1 ml of sonication buffer and centrifuged at 25,000 x g for 10 min at 4°C.
  • the pellet (nucleus fraction) is resuspended in 1 ml of sonication buffer and added to an equal volume of 2 x SDS sample buffer.
  • the supernatant obtained above (after the first sonication) is again centrifuged at 100,000 x g for 40 min at 4°C.
  • the supernatant (cytosolic fraction) is removed and added to an equal volume of 2 x concentrated SDS sample buffer.
  • the remaining pellet (membrane fraction) is washed and dissolved in sonication buffer and SDS sample buffer as described above. Protein samples are analyzed by electrophoresis on 10% polyacrylamide gels, according to the Lae mli method (Konopka, J.B., et al., Mol. Cell.
  • the proteins are transfe ⁇ ed from the gels on a 0.45- ⁇ m polyvinylidine difluoride membrane for subsequent immunoblot analysis. Primary binding of antibodies is detected using anti-IgG second antibodies conjugated to horseradish peroxidase.
  • CMK cells or U3T3 are grown on cover slips to approximately 50% confluence and are washed with PBS (pH 7.4) after removing the medium.
  • the cells are prefixed for 1 min at 37°C in 1% paraformaldehyde containing 0.075% Triton X-100, rinsed with PBS and then fixed for 10 min with 4% paraformaldehyde. After the fixation step, cells are rinsed in PBS, quenched in PBS with 0.1 and finally rinsed again in PBS.
  • the cells are first blocked with a blocking solution (3% bovine serum albumin in PBS) and incubated for 1 h at 37°C.
  • the cells are then incubated for 1 h at 37°C with antiserum (1 :100 dilution or with preimmune rabbit serum (1 :100) (see below). After the incubation with the primary antibody, the cells are washed in PBS containing 3% bovine and serum albumin and 0.1 % Tween 20 and incubated for 1 hour at 37 °C in a fluorescein-conjugated donkey anti-rabbit IgG (Jackson Immunoresearch, Maine), diluted 1 :100 in blocking solution.
  • coverslips are washed in PBS (pH 8.0), and glycerol is added to each 5 coverslip before mounting on glass slides and sealing with clear nail polish. All glass slides were examined with a Zeiss Axiophot microscope.
  • the above methods for detection of a given mutant protein or nucleic acid are o applicable to analyses involving tissues, cell lines and bodily fluids (e.g. cerebrospinal liquor or blood, including but not limited to venous, arterial and cord blood) suspected of containing the marker protein.
  • bodily fluids e.g. cerebrospinal liquor or blood, including but not limited to venous, arterial and cord blood
  • tissue suspected of being in a diseased state may be analyzed, it having been previously observed according to the invention that tissue of that particular diseased state contains detectable levels of hybrid wild- type/nonsense proteins relative to healthy tissue.
  • An aliquot of the suspect sample and a heakfiy control sample are provided and admixed with an effective amount of an antibody specific for the hybrid wild- type/nonsense protein, as herein described, and an indicating group.
  • the admixture is typically incubated, as is known, for a time sufficient to permit an immune reaction to occur.
  • the incubated admixture is then assayed for the presence of an immune reaction as indicated by the indicating group.
  • the relative levels of the hybrid wild- type/nonsense protein in the suspect sample and the control sample are then compared, allowing for diagnosis of a diseased or healthy state in the suspect sample.
  • analyzing for the presence of the hybrid wild- type/nonsense protein may, of course, be performed using analysis for the coding RNA, e.g., via Northern blot or RNA dot blot analysis, both of which are conventional and known in the art.
  • transcript mutant RNA molecules evidence supporting the presence of transcript mutant RNA molecules is that in homozygous Brattleboro hypothalamus cells, vasopressin cDNAs having the frameshift mutation were observed in 1 in 100 colonies, where as genomic vasopressin DNA having the frameshift mutation was not identified.
  • RNA molecule containing a frameshift mutation i.e., a frameshifted transcript
  • the disease is treatable according to the invention as follows: by administering to a patient in need thereof enzymes which serve to selectively eliminate frameshifted RNA via cleavage, e.g., ribozymes; by administering the wild-type version of the mutant RNA, preferably in substantially uncleavable form, by administering the wild-type version of the hybrid wild-type/nonsense protein; or by administering oligonucleotides or sequences encoding oligonucleotides complementary to a mutant RNA to a cell in order to form a nucleic acid duplex which renders the mutant RNA untranslatable.
  • a patient in need thereof will include a patient exhibiting symptoms of the disease, even those patients suspected of developing the disease, i.e., who are monitored according to the invention by measuring the a tissue sample, e.g., the cerebrospinal fluid, for the presence of frameshifted peptides (e.g. peptides having an amino acid sequence in the +1 or +2 reading frame).
  • a tissue sample e.g., the cerebrospinal fluid
  • a ribozyme may be delivered to affected or susceptible cells leading to the cleavage of the mutant RNA and resultant inability of the cell to translate the mutant RNA into mutant protein.
  • the wild-type protein if not already produced by the cell, may be provided in protein form or via administering the 5 wild-type RNA to the cell along with the ribozyme.
  • the wild-type RNA may be engineered so as to contain a sequence that is distinguishable from the mutant RNA sequence other than simply at the level of the GAGA or CTCT mutation.
  • the mutant RNA may contain third base silent mutations, i.e., which do not change the coding sequence of the RNA, but which render the wild-type RNA less or o substantially unsusceptible to cleavage by the ribozyme.
  • third base silent mutations i.e., which do not change the coding sequence of the RNA, but which render the wild-type RNA less or o substantially unsusceptible to cleavage by the ribozyme.
  • decreasing the percentage of mutant RNA and increasing the percentage of the correct protein produced in relation to the hybrid wild-type/nonsense protein will reduce or prevent further progression of the disease, and possibly reverse the diseased state.
  • the mutant protein may be routed to the proteasomal and/or lysosomal system or just secreted (e.g. by the constitutive or regulated pathway)and degraded elsewhere.
  • the mutant protein will be accumulated in the membrane
  • the wild-type version of the mutated RNA encodes the co ⁇ ect protein.
  • prefe ⁇ ed wild-type sequences include the RNAs encoded by the ⁇ amyloid precursor protein gene, the Tau gene, the ubiquitin B gene, the apolipoprotein-E 4 gene, the microtubule associated protein II (MAP2) gene, the neurofilament protein genes (L, M and H), the presenilin I and II genes, Big Tau, GFAP, P53, BCL2, Semaphorin III, HUPF-1, HMG and NSP-A.
  • the sequences of these genes are provided herein in the figures.
  • RNAs are encoded by the alpha and beta tubulin genes, the sequences of which are found in Cowan et al., Mol. Cell. Biol, 3, 1738-1745(1983) and Lewis et al., J. Mol. Biol. 182, 11-20(1985), respectively.
  • RNAs are encoded by gene sequences which include but are not limited to the human p53 gene and the BCL-2 gene.
  • Mammalian phosphoprotein p53 has been shown to play an essential role in regulation of cell division and is required for the transition from phase GO to Gl of the cell cycle.
  • P53 is normally present in very low levels in normal cells and is believed to be a tumor suppressor gene; when present at high levels, p53 has been shown to play a role in transformation and malignancy.
  • P53 gene alleles from normal and malignant tissues have been shown to contain Bglll site polymorphism (Buchman et al., 1988, Gene 70:245).
  • the p53 coding region contains several GAGA motifs, e.g., GAGAC at position 1476 of the sequence published in Buchman et al., GAGA at position 1498; GAGA at position 1643; and GAGA at position 1713, which motifs present candidate sites for frameshift RNAs according to the invention.
  • a frameshift mutation within a p53 RNA thus may lead to loss of the natural p53 tumor suppressor function. Detection of such a mutation in p53 may be diagnostic of pre- malignancy or malignancy, and treatment as described herein which results in co ⁇ ection of p53 function may restore tumor suppressor function.
  • the invention also encompasses methods of combatting diseases caused by at least one an RNA having one or more GA, GT or CT deletions giving rise to a frameshift mutation by targeting the RNA transcript.
  • a frameshift mutation within an RNA may be co ⁇ ected at the level of the frameshifted RNA via cleavage using a ribozyme having specificity for the mutant RNA sequence (see Denman et al., Arch. Of Biochem. Biophysics. 323,71-78,1995), and eliminating the mutant mRNA.
  • the disease associated with the frameshifted RNA is thus treated by administering an appropriate ribozyme, or sequences encoding the ribozyme, to the patient.
  • Ribozymes of selected specificities may be made as described by Sullenger & Cech, Nature 371: 619-622, 1994), herein incorporated by reference. Ribozymes and sequences encoding ribozymes may be prepared as described by Tuschl et al., Cu ⁇ . Opin. Struc. Biol. 5:296, 1995 and Wahl et al., Cu ⁇ . Opin. Struc. Biol. 5:282, 1995.
  • the invention also encompasses methods of treating diseases caused by or associated with at least one an RNA having one or more GAGA or CTCT mutations giving rise to a frameshift by delivery of complementary oligonucleotides or sequences encoding complementary oligonucleotides to a target cell containing a frameshifted RNA.
  • the oligonucleotides will have a mutant sequence with respect to the region of the mutant RNA containing the GA, GT or CT deletion, and thus may o serve to form a hybrid in vivo with the mutant RNA, rendering it untranslatable. Oligonucleotides with strong target site binding affinity, i.e., with full target site homology are prefe ⁇ ed.
  • oligonucleotides between 10 - 30 nucleotides in length and containing a CTCT, CTCTG, CTCTC, CTCTT or CTCTA motif or a GAGA, GAGAG, GAGAC, GAGAT or GAGAA motif.
  • Disease treatment according to the invention is described below and includes preparation of the administered substance and administration of the substance to a patient suffering from a disease according to the invention.
  • “substance” refers to any one of the following: a ribozyme, a nucleic acid sequence encoding a ribozyme, a wild-type transcript, an antisense mutant RNA or DNA or a nucleic acid sequence encoding an antisense sequence, a wild type protein encoded by the wild type gene, an antibody specific for the frameshifted (nonsense) protein.
  • Example 5 Treatment using ribozymes according to the invention is described.
  • Example 6 administration of vectors is described.
  • Example 7 administration of proteins, ribozymes, or nucleic acid vectors using liposomes is described.
  • Example 8 delivery of these substances across the blood-brain barrier is described.
  • Example 9 methods ofdelivering cells comprising a protein, ribozyme or other nucleic acid, such as a vector bearing a gene expression construct, o are described.
  • Preparation and delivery of a ribozyme or nucleic acid sequence encoding a ribozyme which effect or facilitate selective removal of the frameshifted RNA is 5 carried out as follows.
  • the invention thus also encompasses methods of treating diseases caused by the translation of frameshifted mRNA's which are the result of transcriptional infidelity occurring at or adjacent to GAGA or CTCT motifs in the ⁇ -APP and o ubiquitin B genes. It is believed that accumulation of abe ⁇ ant proteins encoded by these messages contributes to the progression of Alzheimer's disease; therefore, elimination of the mutant transcripts is of therapeutic value. It is contemplated according to the invention that the mutant transcripts described herein are rendered untranslatable in a cell via ribozyme-mediated cleavage using ribozymes designed and administered as described herein.
  • Ribozymes of the hammerhead class are the smallest known, and lend themselves both to in vitro synthesis and delivery to cells (summarized by Sullivan, J. Invest. Dermatol. 103: 85S-98S, 1994; Usman et al., Curr. Opin. Struct. Biol. 6: 527- 533, 1996). It is required of hammerhead cleavage targets that they comprise the sequence motif UH, wherein H denotes the ribonucleotides A, U, or C, but not G; the sequence is cleaved following the H.
  • the core functional unit of the hammerhead o ribozyme is a tripartite structure made up of helix I, which hybridizes to mRNA sequences 3' of the cleavage site, helix II, a 22 ribonucleotide catalytic domain which mediates the cleavage reaction, and helixIII, which hybridizes to sequences 5' of- and including the ' TJ" of the UH cleavage motif (Haseloff and Gerlach, Nature 334: 585- 591, 1988; Ruf ⁇ er et al, Biochemistry 33: 10695-10702, 1990).
  • helix I is 3 to 5 ribonucleotides in length, relative to 9 to 13 ribonucleotides for helix III (Tabler et al, Nucleic Acids Res.
  • Mutant ubiquitin B transcripts can be removed from cells via the application of hammerhead ribozymes delivered to these cells in liposome vectors.
  • the invention comprises use of these ribozymes to recognize and cleave mutant transcripts at a site 5' to the GAGA or GGT-containing site that is the source of polymerase slippage during transcription, thereby ridding the cells of the frame-shifted portion of the translated products of these defective messages.
  • the sequence immediately preceding the GAGA motif in the ubiquitin transcript is GCGUCU, which includes the cleavage recognition motif UC.
  • helix I the sequence ideally bound by helix I for a particular mutant is GAG; however, in that such a ribozyme would be expected to bind the mutant and wild-type transcripts with equal efficiency, helix I must be lengthened to include four more nucleotides, such that all seven bases will hybridize to the mutant transcript, " while sufficient mismatch to destabilize binding to the wild-type sequence will result.
  • cleavage of both of the wild-type transcript via hammerhead ribozymes may be unavoidable, and its replacement with a cleavage-resistant transcript must be undertaken in concert with removal of mutant transcripts (see Table 10 for possible sequence substitutions resulting in a cleavage- resistant transcript); here, the ribozyme is designed to cleave both types of message at any UH site 5' of the first GAGA motif.
  • the 96 base pairs can be fused to a minigene engineered such that alterations are made in the ribozyme recognition site to prevent cleavage of the replacement ⁇ -APP transcript and in the GAGA motifs to inhibit slippage of the transcriptional machinery such as produces the mutant transcripts in the first place; these replacements should be performed such that translationally "silent" mutations are introduced in each case. Examples of such changes are shown in Table 10. EXAMPLE , Preparation of Nucleic Acid Vectors
  • Sequences encoding ribozymes or a wild-type version of a mutant RNA, or an antisense (complementary) mutant oligonucleotide sequence may be cloned into an appropriate vector for expression in a desired mammalian cell.
  • the vector will include a promoter that is expressed in the target cell type, and also may include an enhancer and locus control region, as selected for expression in ' a given cell type. Examples of vectors useful according to the invention include but are not limited to any vector which results in successful transfer of the coding sequences to the target mammalian cell.
  • a nucleic acid may be transfected for use in the invention using a viral (e.g.
  • non-viral vectors include, but are not limited to, plasmids, linear nucleic acid molecules, artificial chromomosomes and episomal vectors.
  • Expression of heterologous genes has been observed after injection of plasmid DNA into muscle (Wolff J. A. et al., 1990, Science. 247: 1465-1468; Carson D.A. et al., US Patent No. 5,580,859), thyroid (Sykes et al., 1994, Human Gene Ther.. 5: 837-844), melanoma (Vile et al, 1993, Cancer Res..
  • SAX is a moloney virus based vector with the neoR gene promoted from the retroviral LTR and the human ADA gene promoted from an internal SV40 promoter.
  • the SAX vector may be engineered by one of skill in the art to contain the coding sequence for a ribozyme, or a wild-type RNA, or a selected antisense sequence, identified as described herein, e.g., by substituting the desired coding region for the hADA coding region in the SAX vector.
  • Expression vectors are known in the art which encode, or may be engineered to encode, a selected ribozyme. Yuyama et al., Nucl. Acids Res. 22:5060, 1994, describe a multifunctional expression vector encoding several ribozymes. This vector may be adapted to encoded a ribozyme of a selected specificity by substituting one or both ribozyme sequences in the vector for a selected ribozyme sequence. Zhou et al., Gene 149:33, 1994, and Yamada et al., Virology 205;121, 1994, describe retroviral transduction of ribozyme sequences into T cells.
  • retroviral vectors may be adapted to encode a selected ribozyme sequence.
  • nucleic acid molecules are administered in a manner compatible with the dosage formulation, and in such amount as will be prophylactically and/or therapeutically effective.
  • the dosage to be administered is directly proportional to the the amount needed per cell and the number of cells to be transfected, with a co ⁇ ection factor for the efficiency of uptake of the molecules.
  • the strength of the associated transcriptional regulatory seuqences also must be considered in calculating the number of nucleic acid molecules per target cell that will result in adequate levels of the encoded product.
  • Suitable dosage ranges are on the order of, where a gene expression construct is administered, 0.5- to l ⁇ g, or 1- lO ⁇ g, or optionally 10- 100 ⁇ g of nucleic acid in a single dose. It is conceivable that dosages of up to lmg may be advantageously used. Note that the number of molar equivalents per cell vary with the size of the construct, and that absolute amounts of DNA used should be adjusted accordingly to ensure adequate gene copy number when large constructs are injected.
  • Nucleic acid molecules to be administered according to the invention may, for example, be formulated in a physiologically acceptable diluent such as water, phosphate buffered saline, or saline, and further may include an adjuvant; however, it is contemplated that other formulations may advantageously be employed.
  • Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or o alum are materials well known in the art.
  • Administration of a nucleic acid molecule as described herein may be either localized or systemic. Methods for both localized and systemic administration of a pharmacological composition are well known in the art.
  • Nucleic acid constructs of use in the invention can be given in a single- or multiple dose.
  • a multiple dose schedule is one in which a primary course of administration can include 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or reinforce the cellular level of the transfected nucleic acid. Such intervals are dependent on the continued need of the recipient for the therapeutic nucleic acid, the ability of a given nucleic acid to self- replicate in a mammalian cell if it does not become integrated into the recipient's genome and the half-life of a non-renewable nucleic acid (e.g. a molecule that will not self-replicate).
  • a non-renewable nucleic acid e.g. a molecule that will not self-replicate
  • a nucleic acid may be encoded by sequences of a vector that will self-replicate in the target cells.
  • the efficacy of transfection and subsequent maintenance of the nucleic acid molecules may be assayed either by monitoring the activity of a marker gene, which may additionally be comprised by the transfected construct, or by the direct measurement of either the protein product encoded by the gene of interest or the reduction in the levels of a protein the production of which it is designed to inhibit.
  • the assays can be performed using conventional molecular and biochemical techniques, such as are known to one skilled in the art.
  • the success of treatment using nucleic acid molecules in the invention may be determined by the assessment of known clinical indicators (e.g., for a neurodegenerative disease, loss of cognitive or motor function).
  • the progression or (if treatment is undertaken prophylactically on an patient believed to be at risk of disease) development of such symptoms in a treated individual is compared to those observed in untreated control subjects; if an improvement in the treated patient's condition is observed relative to that of control subjects, treatment is judged to be o effective.
  • the making of such an assessment is well within the knowledge of one of skill in the art.
  • Liposomes which are used to administer the substances described herein, e.g., a ribozyme can be of various types and can have various compositions. -The primary restrictions are that the liposomes should not be toxic to the living cells and that they should deliver their contents into the interior of the cells being treated.
  • the use of pH sensitive liposomes to mediate the cytoplasmic delivery of calcein and FITC dextran has been described (see Straubinger et al., Cell 32:1069- 1079, 1983; and Straubinger et al, FEBS Letters 179:148-154, 1985.
  • the liposomes may be of various sizes and may have either one or several membrane layers separating the internal and external compartments.
  • the most important elements in liposome structure are that a sufficient amount of enzyme or nucleic acid be sequestered so that only one or a few liposomes are required to enter each cell for delivery of the substance, and that the liposome be resistant to disruption.
  • Liposome structures include small unilamellar vesicles (SUVs, less than 250 angstroms in diameter), large unilamellar vesicles (LUVs, greater than 500 angstroms in diameter), and multilamellar vesicles (MLs).
  • SUVs small unilamellar vesicles
  • LUVs large unilamellar vesicles
  • MLs multilamellar vesicles
  • SUVs can be isolated from other liposomes and unincorporated enzyme by molecular weight can be isolated from other liposomes and unincorporated enzyme by molecular sieve chromatography, which is precise but time consuming and dilutes the liposomes, or differential centrifugation, which is rapid but produces a wider range of liposome sizes.
  • the liposomes may be made from natural and synthetic phospholipids, glycolipids, and other lipids and lipid congeners; cholesterol, cholesterol derivatives and other cholesterol congeners; charged species which impart a net charge to the membrane; reactive species which can react after liposome formation to link additional molecules to the liposome membrane; and other lipid soluble compounds which have chemical or biological activity.
  • the liposomes useful according to the invention may be prepared, for example, as described in U.S. Patent No. 5,296,231, which describes preparation of liposomes containing a ribozyme, although it should be borne in mind that liposomes useful according to the invention may contain any one of the substances as herein described. Briefly, by combining a phospholipid component with an aqueous component containing the ribozyme (or desired substance) under conditions which will result in vesicle formation. The phospholipid concentration must be sufficient to form lamellar structures, and the aqueous component must be compatible with biological stability of the enzyme.
  • Methods for combining the phospholipids onto glass and then vesicles will form include: drying the phospholipids onto glass and then dispersing them in the aqueous component; injecting phospholipids dissolved in a vaporizing or non-vaporizing organic solvent into the aqueous component which has previously been heated; and dissolving phospholipids in the aqueous phase with detergents and then removing the detergent by dialysis.
  • the concentration of the ribozyme in the aqueous component can be increased by lyophilizing the enzyme onto dried phospholipids and then rehydrating the mixture with a reduced volume of aqueous buffer.
  • SUVs can be produced from the foregoing mixtures either by sonication or by dispersing the mixture through either small bore tubing or through the small orifice of a French Press.
  • Ribozymes incorporated into liposomes can be administered to living cells internally or topically. Internal administration to animals or humans requires that the o liposomes be pyrogen-free and sterile. To eliminate pyrogens, pyrogen-free raw materials, including all chemicals, enzymes, and water, are used to form the liposomes. Sterilization can be performed by filtration of the liposomes through 0.2 micron filters. For injection, the liposomes are suspended in a sterile, pyrogen-free buffer at a physiologically effective concentration. Topical administration also requires that the liposome preparation be pyrogen-free, and sterility is desirable.
  • a physiologically effective concentration of liposomes can be suspended in a buffered polymeric glycol gel for even application to the skin.
  • the gel should not include non-ionic detergents which can disrupt liposome membranes.
  • Other vehicles can also be used to topically administer the liposomes.
  • the concentration of the substance in the final preparation can vary over a wide range, a typical concentration being on the order of 50 ug/ml.
  • concentrations of the substance can be used, e.g., on the order of 0.01 to 1.0 ug/ml for liposomes administered to cells internally.
  • higher liposome concentrations used e.g., ten or more times higher.
  • a substance to be administered may be co-administered with a polypeptide, for example a lipophilic polypeptide that increases permeability at the blood-brain barrier.
  • a polypeptide for example a lipophilic polypeptide that increases permeability at the blood-brain barrier.
  • 5 polypeptides include but are not limited to bradykinin and receptor mediated permeabilizers, such as A-7 or its conformational analogues, as described in U.S. Patent Nos. 5,112,596 and 5,268,164.
  • the permeabilizing polypeptide allows the co- administered ribozyme, coding sequence or liposome to penetrate the blood-brain barrier and arrive in the cerebrospinal fluid compartment of the brain, where the o ribozyme, or coding sequence may then reach and enter a target neuronal cell.
  • the substance to be administered may be coupled to a steroidal estrogel or androgel to increase binding to steroid receptors and thus access to the brain.
  • Another exemplary method for administering a substance such as a ribozyme, antibody, nucleic acids, or liposomes containing such molecules, according to the invention includes forming a complex between the substance to be administered and an antibody that is reactive with a transferrin receptor, as described in U.S. Patent No. 5,182,107.
  • the complex may include a cleavable or-ribn-cleavable linker and is admimstered under conditions whereby binding of the antibody to a transferrin receptor on a brain capillary endothelial cell occurs and the substance is transfe ⁇ ed across the blood-brain barrier in active form.
  • a therapeutic nucleic acid for use not only in in vivo therapy (i.e., that in which a nucleic acid is administered directly to a patient for uptake by- and subsequent expression in cells in situ) but also in ex vivo therapy (i.e., that in which a nucleic acid is administered to cultured or explanted cells in vitro, which transfected cells are subsequently transplanted into the clinical patient in order to supply a therapeutic product).
  • ex vivo therapy i.e., that in which a nucleic acid is administered to cultured or explanted cells in vitro, which transfected cells are subsequently transplanted into the clinical patient in order to supply a therapeutic product.
  • RNA e.g., an antisense RNA or ribozyme
  • a cell type may be used according to the invention which is amenable to methods of nucleic acid transfection such as are known in the art.
  • Such cells may include cells of an organism of the same species as the recipient organism, or even cells harvested from the recipient organism itself for ex vivo nucleic acid transfection o prior to re-introduction.
  • Such autologous cell transplants are known in the art.
  • bone marrow transplantation in which bone marrow is drawn either from a donor or from a clinical patient (for example, one who is about to receive a cytotoxic treatment, such as high doses of ionizing radiation), and then transplanted into the patient via injection, whereupon the cells re-colonize bones and other organs of the hematopoietic system, a.
  • a cytotoxic treatment such as high doses of ionizing radiation
  • the number of transfected cells which are administered to a recipient organism is determined by dividing the absolute amount of therapeutic or other gene product required by the organism by the average amount of such an agent which is produced by a transfected cell.
  • steady-state plasmid copy number varies depending on the strength of its origin of replication as well as factors determined by the host cell environment, the availability of nucleotides and replicative enzyme complexes, as does the level of expression of the gene of interest encompassed by the plasmid, which level likewise is determined by the strength of its associated promoter and the availability of nucleotides and transcription factors in a given host cell background.
  • the level of expression per cell of a given gene of interest must be determined empirically prior to administration of cells to a recipient.
  • a multiple dose schedule is one in which a primary course of administration can include 1-10 separate doses, followed by other doses given at subsequent time intervals required to maintain and or 5 reinforce the cellular level of the transfected nucleic acid. Such intervals are dependent on the continued need of the recipient for the therapeutic gene product.
  • the transfected cells will be replenished on a regular o schedule, such as monthly or semi-monthly, unless such cells are able to colonize the recipient patient in permanent fashion, such as is true in the case of a successful bone- ma ⁇ ow cell transplant.
  • a regular o schedule such as monthly or semi-monthly
  • nucleic acid vector capable of replication in the transfected cell the absolute amount of nucleic acid which is transfected into cells prior to transplantation is not critical, since in cells receiving at least one copy of such a vector, the vector will replicate until an equilibrium copy-number is achieved.
  • an amount of vector equivalent to between 1 and 10 copies thereof per cell to be transfected may be used; one of skill in the art may adjust the ratio of plasmid molecules to cells as is necessary to optimize vector uptake.
  • vectors or transfection techniques which result in the stable integration of the gene of interest into the chromosome of the transfected cell, so as to avoid the need to maintain selection for cells bearing the vector following transplantation into a recipient multicellular organism, such as a human.
  • a cell type which is commonly transplanted between individuals of a single species (or, even, from an individual to a cell culture system and back to the same individual) is that of hematopoietic stem cells (HSCs), which are found in bone ma ⁇ ow; such cells have the advantage that they are amenable to nucleic acid transfection while in culture, and are, therefore, well suited for use in the invention.
  • HSCs hematopoietic stem cells
  • HSCs Cultures of HSCs are transfected with a minimal plasmid comprising an operator sequence and a gene of interest and the transfected cells administered to a recipient mammal in need of the product of this gene.
  • Transfection of hematopoietic stem cells is described in Mannion-Henderson et al., 1995, Exp. Hematol.. 23: 1628; Schiffmann et al., 1995, BlQpi, 86: 1218: Williams. 1990. Bone Ma ⁇ ow Transplant. 5: 141; Boggs, 1990, Int. J. Cell Cloning. 8: 80; Martensson et al., 1987, Eur. J. Immunol..
  • transfected cells proceeds according to methods established for that of non-transfected cells, as described below.
  • the transplantation of hematopoietic cells, such as in a bone marrow transplant, is commonly performed in the art by procedures such as those described by Thomas et al. (1975, New England J. Med.. 292: 832-843) and modifications thereof.
  • bone marrow cells which population comprises a small number of pluripotent hematopoietic stem cells, or HSCs
  • HSCs pluripotent hematopoietic stem cells
  • HSCs While as few as 1-10 HSCs are, in theory, able to colonize and repopulate a lethally-i ⁇ adiated recipient mammal over time, it is advantageous to optimize the rate at which repopulation occurs in a human bone ma ⁇ ow transplant patient; therefore, a transplanted bone ma ⁇ ow sample comprising 10 to 100, or even 100 to 1000 HSCs should be administered in order to be therapeutically effective.
  • lymphoid and parenchymal cells are of use in the invention.
  • parenchymal cells include those of the islets of Langerhans, the thyroid, the adrenal cortex, muscles, cartilagenous- or other synovial tissue, the kidneys, epithelial tissues (both external and internal, particularly that of the intestinal lumen, lung, heart, liver, kidney, neurons and synovial cells) and, in particular, the nervous system.
  • transplanted cells expressing a high level of activated NFKB (a high NFKB "set point"), while still subject to destruction by autoimmune host lymphocytes, would enjoy the advantage of robust proliferative capacity in order to multiply at a rate surpassing that of cell killing, thereby providing a long-lived population of therapeutic cells to the recipient organism.
  • Such cells may be transfected with gene expression constructs which result in the production of high levels of activated NFKB, or may be cells obtained from a donor selected for high endogenous NFKB activity, as may be determined in an in vitro transcription assay or DNA protein binding assay by methods well known in the art, using protein extracts drawn from such a donor, which may, itself, be a transgenic mammal.
  • d. Administration of xenogeneic and allogeneic cells
  • transfection and subsequent tranplantation of cells which are obtained from an individual or cell culture system of like species with the recipient organism may be performed, it is equally true that the invention may be practised using cells of another organism (such as a well-characterized eukaryotic microorganism, e.g. yeast, in which appropriate processing of proteins encoded by therapeutic genes is likely and in which useful origins of replication are known). In such a case, certain concerns must be addressed.
  • a well-characterized eukaryotic microorganism e.g. yeast, in which appropriate processing of proteins encoded by therapeutic genes is likely and in which useful origins of replication are known.
  • the transplanted cells when a protein is encoded by the gene of interest, the transplanted cells must produce the protein in a form that may is of use to the recipient organism.
  • Post- translational processing (including, but not limited to, cleavage and patterns of glycosylation) must be consistent with proper function in the recipient.
  • either a protein or an RNA molecule of interest must be made available to the recipient after synthesis, such as by secretion, excretion or exocytosis from the transplanted cell.
  • the protein produced by the transfected cells may be qualitatively compared to the native protein produced by an individual of the same species as the recipient organism by biochemical methods well known in the art of protein chemistry.
  • the latter release of the protein of interest by the cells to be transplanted, may be assayed by isolating protein from culture medium which has been decanted from the transfected cells or from which such cells have been separated (i.e. by centrifugation or filtration), and performing Western analysis using an antibody directed at the protein of interest.
  • isolating protein from culture medium which has been decanted from the transfected cells or from which such cells have been separated i.e. by centrifugation or filtration
  • Western analysis using an antibody directed at the protein of interest i.e. by centrifugation or filtration
  • the cells must be shielded from immune rejection by the recipient organism. It is contemplated that such cells may be transfected with constructs expressing cell-surface markers (e.g. MHC antigens) characteristic of the recipient patient so as to provide them with biochemical camoffage.
  • cell-surface markers e.g. MHC antigens
  • Patents among these are Nos. 4,353,888; 4,409,311; 4,673,566; 4,744,933; 4,798,786; 4,803,168; 4,892,538; 5,01 1,472; 5,158,881 ; 5,182,111; 5,283,187; 5,474,547; 5,498,401 (which is particularly directed to the encapsulation of bacterial and yeast cells in chitosan); 5,550,050; 5,573,934; 5,578,314; 5,620,883; 5,626,561; 5,653,687; 5,686,115; 5,693,513; and 5,698,413, the contents of which are fully incorporated by reference herein.
  • a selectively-permeable outer covering or 'skin' which is biocompatible (i.e., tolerated by both the encapsulated cells and the recipient host), and, optionally, a matrix in- or upon which cells are distributed such that the matrix provides structural support and a substrate to which anchorage-dependent cells may attach themselves.
  • the term "selectively- permeable” refers to materials comprising openings through which small molecules (including molecules of up to about 50,000 M.W. - 100,000 M.W.) may pass, but from which larger molecules, such as antibodies (approximately 150,000 M.W.), are excluded.
  • Suitable covering materials include, but are not limited to, porous and/or polymeric materials such as polyaspartate, polyglutamate, polyacrylates (e.g., acrylic copolymers or RL®, Monsanto Corporation), polyvinylidene fluoride, polyvinylidienes, polyvinyl chloride, polyurethanes, polyurethane isocyanates, polystyrenes, polyamides, cellulose-based polymers (e.g.
  • cellulose acetates and cellulose nitrates polymethyl-acrylate, polyalginate, polysulfones, polyvinyl alcohols, polyethylene oxide, polyacrylonitriles and derivatives, copolymers and/or mixtures thereof, stretched polytetrafluoroethylene (U.S. Pat. Nos. 3,953,566 and 4,187,390, both incorporated herein by reference), stretched polypropylene, stretched polyethylene, porous polyvinylidene fluoride, woven or non-woven collections of fibers or yarns, such as "Angel Hair” (Anderson, Science. 246: 747-749; Thompson et al., 1989, Proc. Natl. Acad. Sci. U.S.A..
  • the matrix material comprising the transfected cells of the invention, is exposed to conditions that induce it to form its own outer covering, as discussed below.
  • the selective permeability of such a covering may be varied by impregnating the void spaces of a porous polymeric material- (e.g., stretched polytetrafluoroethylene) with a hydrogel material.
  • Hydrogel material can be impregnated in substantially all of the void spaces of a porous polymeric material or in only a portion of the void spaces.
  • the selective permeability of the material is varied sharply from an outer cross-sectional area of the material to an inner cross-sectional area of the material.
  • hydrogel material impregnated in a porous polyhmeric material depends in large part on the particular porous polymeric material o used to encapsulate cells for transplant.
  • suitable hydrogel materials include, but are not limited to, HYP AN® Structural Hydrogel (Hymedix International, Inc.; Dayton, NJ), non-fibrogenic alginate, as taught by Dorian in PCT/US93/05461, which is incorporated herein by reference, agarose, alginic acid, carrageenan, collagen, gelatin, polyvinyl alcohol, poly(2-hydroxyethyl methacrylate), poly(N- vinyl-2- pyrrolidone) or gellan gum, either alone or in combination.
  • the matrix typically has a high surface-area:volume ratio, comprising pores or other spaces in- or on which cells may grow and through which fluids may pass; in addition, suitable matrix materials are stable following transplantation into a recipient organism.
  • the matrix comprises an aggregation of multiple particles, fibers or laminae.
  • a matrix may comprise an aqueous solution, such as a physiological buffer or body fluid from the recipient organism (see U.S. Patent No. 5,011,472).
  • Suitable matrix materials include liquid, gelled, polymeric, co-polymeric or particulate formulations of aminated glucopolysachharides (e.g., deacetylated chitin, or "chitosan", which is prepared from the pulverized shells of crabs or other crustaceans, and is commercially available as a dry powder; Cat. # C 3646, Sigma, St. Louis, MO), alginate (U.S. Patent No. 4,409,331), poly- ⁇ -l-5-N-acetylglucosamine (p-GlcNAc) polysaccharide species (either alone of formulated as co-polymer with collagen; see U.S. Patent No.
  • aminated glucopolysachharides e.g., deacetylated chitin, or "chitosan”
  • alginate U.S. Patent No. 4,409,331
  • p-GlcNAc poly- ⁇ -l-5-
  • Encapsulation devices comprising a semi-permeable membrane material, as described above, may be pre-formed, filled with cells (e.g. by injection or other manual means) and then sealed (U.S. Patent Nos. 4,892,538; 5,011,472;
  • sealing may be effectively permanent (e.g. by the use of heat-sealing), semi-permanent (e.g. by the use of a biocompatible adhesive, such as an epoxy, which will not dissolve or degrade in an aqueous environment) or temporary (e.g. by the use of a removable cap or plug, or by shutting of a valve or stopcock).
  • a biocompatible adhesive such as an epoxy, which will not dissolve or degrade in an aqueous environment
  • temporary e.g. by the use of a removable cap or plug, or by shutting of a valve or stopcock
  • a liquid or semi-liquid (i.e., gelled) cell/matrix mixture droplet is suspended either in an agent which induces 'curing' or crosslinking of the outer layer of matrix material to form a semi-permeable barrier (U.S. Patent Nos. 4,798,786 and 5,489,401) or in a solution of polymeric material (or monomers thereof), which will polymerize and/or crosslink upon contact with the cell/matrix droplet such that a semi-permeable membrane is deposited thereon (U.S. Patent Nos. 4,353,888; 4,673,566; 4,744,933; 5,620,883; and 5,693,513).
  • Implantation of such a device is achieved surgically, via standard techniques, to a site at or near the anatomical location to which the product encoded by the gene on the gene of interest is to be delivered, as is deemed safest and most expedient.
  • a device may take a convenient shape, including, but not limited to, that of a sphere, pellet or other capsule shape, disk, rod or tube; often, the shape of the device is determined by its method of synthesis.
  • one which is formed by co- extrusion of a cell suspension and a polymeric covering material is typically tubular, while one formed by the deposition of a covering on droplets comprising cells in matrix material might be spherical.
  • the encapsulation devices described above are typically small (most usefully, lO ⁇ m to 1mm in diameter, so as to permit efficient diffusion of substances back and forth between the outer covering and the cells most deeply embedded in the matrix), and it is contemplated that such devices may carry between 10 and 10 10 cells each. Should the need for larger numbers of cells be anticipated, a plurality (2, 10 or even 100 or more) of such in vivo culturing devices may be made and implanted in a given recipient organism.
  • An encapsulated cell device may be intended for permanent installation; alternatively, retrieval of the device may be desirable, whether to terminate delivery of the product of the gene of interest to the recipient organism at the discretion of one of skill in the art, such as a physician (who must determine on a case-by-case basis the length of time for which a given cell implant is beneficial to the recipient organism) or to replenish the device with fresh cells after long-term use (i.e. months to years).
  • an implantation device may usefully comprise a retrieval aid, such as a guidewire, and a cap or other port, such as may be opened and re-sealed in order to gain access to the cell reservoir, both as described in U.S. Patent No. 4,892,538.
  • U.S. Patent No. 4,673,566 discloses successful maintenance of normal blood sugar levels in a diabetic rat into which encapsulated rat islet of Langerhans cells were implanted; two administrations of 3,000 cells each together were effective for six months, while a single dose of 1 ,000 cells was effective for two months.
  • the efficacy of the transfected cells so administered and their subsequent maintenance in the recipient host may be assayed either by monitoring the activity of a marker gene, which may additionally be comprised by the transfected construct, or by the direct measurement of either the product (e.g. a protein) encoded by the gene of interest or the reduction in the levels of a protein the production of which it (an antisense message or ribozyme) is designed to inhibit.
  • the assays can be performed using conventional molecular and biochemical techniques, such as are known to one skilled in the art, or may comprise histological sampling (i.e., biopsy) and examination of tranplanted cells or organs.
  • a patient that is subject to a disease state which is associated with a frameshift mutation may be treated in accordance with the invention, as described above, via in vivo, ex vivo or in vitro methods.
  • a ribozyme or a nucleic acid vector encoding a ribozyme, a wild-type RNA, an antisense RNA or DNA or a sequence encoding the antisense RNA, or a wild-type version of a hybrid wild-type/nonsense protein can be administered to the patient, preferably in a pharmaceutically acceptable delivery vehicle and a biologically compatible solution, by ingestion, injection, inhalation or any number of other methods.
  • the dosages administered will vary from patient to patient; an "effective dose" will be determined by the level of enhancement of function of the transfe ⁇ ed genetic material balanced o against any risk of deleterious side effects. Monitoring gene expression and/or the presence or levels of the encoded mutant RNA or protein or its corresponding "sense" protein will assist in selecting and adjusting the dosages admimstered.
  • a composition including a nucleoprotein such as a ribozyme will be admimstered in single or multiple doses, as determined by the physician, in the range of 50 ug - 1 mg, or within the range of 100 ug - 500 ug.
  • a composition including an oligonucleotide will be administered in a single dose in the range of 5 ng - 10 ug, or within the range of 100 ng - 500 ng.
  • a composition including a wild-type RNA or a vector will be administered in a single dose in the range of 10 ng - 100 ug/kg body weight, preferably in the range of 100 ng - 10 ug/kg body weight, such that at least one copy of the sequence is delivered to each target cell.
  • a composition including a protein will be administered in single or multiple doses, as determined by the physician, in the range of 10 ug - 1 mg, or within the range of 100 ug - 50 ug. Any of the above dosages may be administered according to the body weight of the patient, as determined by the physician.
  • Ex vivo transduction is also contemplated within the present invention. Cell populations can be removed from the patient or otherwise provided, transduced with a vector in accordance with the invention, then reintroduced into the patient.
  • the number of cells reintroduced into the patient will depend upon the efficiency of vector transfer, and will generally be in the range of 10 4 - 10 6 transduced cells/patient.
  • the cells targeted for ex vivo gene transfer in accordance with the invention include any cells to which the delivery of the vector is desired, for example, neuronal cells or stem cells.
  • Protein, nucleic acid, or cells administered according to the invention is preferably administered in admixture with a pharmaceutically acceptable carrier substance, e.g., magnesium carbonate, lactose, or a phospholipid to form a micelle, the carrier and protein, nucleic acid or cell together can form a therapeutic composition, e.g., a pill, tablet, capsule or liquid for oral administration to the mammal.
  • a pharmaceutically acceptable carrier substance e.g., magnesium carbonate, lactose, or a phospholipid to form a micelle
  • the carrier and protein, nucleic acid or cell together can form a therapeutic composition, e.g., a pill, tablet, capsule or liquid for oral administration to the mammal.
  • Other forms of compositions are also envisioned, e.g., a liquid capable of being administered nasally as drops or spray, or a liquid capable of intravenous, parenteral, subcutaneous, or intraperitoneal administration.
  • the substance administered may be in the form of a bio
  • the invention encompasses kits for diagnosis or treatment of diseases according to the invention.
  • a diagnostic kit includes suitable packaging materials and one or more of the following reagents: a nucleic acid probe as defined hereinabove, and optionally means for detecting the probe when bound to its complementary sequences.
  • the nucleic acid probe may be labeled, e.g., radiolabeled, fluorescently labeled, etc., or may be detected via indirect labeling techniques, e.g., using a biotin/avidin system, well known in the art.
  • a diagnostic system preferably in kit form, comprises yet another embodiment of this invention.
  • This system is useful for assaying the presence of a hybrid wild-type/nonsense protein or its derivative in cells by the formation of an immune complex.
  • This system includes at least one package that contains an antibody of this invention.
  • a kit also may include a positive tissue sample control.
  • Antibodies are also utilized along with an "indicating group” also sometimes refe ⁇ ed to as a "label”. The indicating group or label is utilized in conjunction with the antibody as a means for determining whether an immune reaction has taken place, and in some instances for determining the extent of such a reaction.
  • indicating group or “label” are used herein to include single atoms and molecules that are linked to the antibody or used separately, and whether those atoms or molecules are used alone or in conjunction with additional reagents. Such indicating groups or labels are themselves well-known in immunochemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel antibodies, methods and/or systems.
  • an antigen-specific antibody or antibody fragment is detectably o labeled by linking the same to an enzyme and use it in an EIA, or enzyme-linked immunosorbent assay (ELISA).
  • This enzyme when later exposed to a substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, flourometric or, most preferably, by visual means.
  • the substrate may be a chromogenic substrate which generates a reaction product visible to the naked eye.
  • Enzymes which can be used to detectably label the binding protein which is specific for the desired detectable mutant protein, inGl ⁇ de but are not limited to, alkaline phosphatase, horseradish peroxidase, glucose-6-phosphate dehydrogenase, staphylococcal nuclease, delta- V-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, asparaginase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
  • radioactively labeling the binding protein for example, the antibody
  • the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
  • Isotopes which are particularly useful for the purpose of the present invention are: 3 H, 131 I, l4 C, and preferably 125 I.
  • the first or second binding protein can be labeled with a fluorescent compound.
  • fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o- phthaldehyde and fluorescamine.
  • the first or second binding protein also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent- tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds examples include luminol, isoluminol, theromatic acridinium o ester, imidazole, acridinium salt and oxalate ester.
  • a bioluminescent compound may be used to label the first or second binding protein. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined 5 by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.
  • the invention also includes diagnostic reagents for use in the present invention, such as nucleic acid sequences, probes and antibody molecules, and or positive tissue controls, as described above, and kits including such reagents for use in o diagnosing or treating a disease.
  • diagnostic reagents for use in the present invention such as nucleic acid sequences, probes and antibody molecules, and or positive tissue controls, as described above, and kits including such reagents for use in o diagnosing or treating a disease.
  • An indicating group or label is preferably supplied along with the antibody and may be packaged therewith or packaged separately. Additional reagents such as hydrogen peroxide and diaminobenzidine, and nickel ammonium sulfate may also be included in the system when an indicating group such as HRP is utilized. Such 5 materials are readily available in commerce, as are many indicating groups, and need not be supplied along with the diagnostic system. In addition, some reagents such as hydrogen peroxide decompose on standing, or are otherwise short-lived like some radioactive elements, and are better supplied by the end-user.
  • AD Alzheimer's disease
  • VEAD Alzheimer's disease
  • LOAD LOAD
  • ApoE4 polymorphism one or two E4 alleles.
  • Other risk factors for late onset AD are butyrylcholinesterase and cytochrome c oxidase.
  • NBB/ Age Sex Dementia GDS Postmortem Fixation Brain Cause of death autopsy (years) (m/f) duration delay duration weight no (years) (h) (days) (g)
  • NBB Netherlands Brain Bank
  • GDS Global deterioration scale (B. Reisberg, F.H. Ferris, M.J. DeLeon and T. Crook, Am. J. Psych. 139, 1136, 1982). 'non-demented
  • NBB Netherlands Brain Bank, "Number of plaques (all types) [1] and tangles as revealed by Congo Red and Bodian silver staining: a) few, b) moderate, c) many.
  • Table 4 Immunoreactivities in the human temporal cortex (Brodman area 38) for mutant ⁇ amyloid precursor protein and ubiquitin-B, the mRNA of which is expressed in the +1 reading frame ( ⁇ APP' 1 and Ubi-B *1 ) Tissues were obtained from controls and neuropathologicaliy confirmed Alzheimer cases. Down syndrome patients showed Alzheimer pathology
  • NBB Netherlands Brain Bank, "Number of plaques (all types) [1] and tangles as revealed by Congo Red and Bodian silver staining a) few, b) moderate, c) many Table 5 Immunoreactivities in the human hippocampus for mutant ⁇ amyloid precursor protein and ubiquitin-B, the mRNA of which is expressed in the +1 reading frame ( ⁇ APP *1 and Ubi-B *1 ). Tissues were obtained from controls and neuropathologically confirmed Alzheimer and Down syndrome cases.
  • NBB Netherlands Brain Bank, * Number of plaques (all types) [1] and tangles as revealed by Congo Red and Bodian silver staining: a) few, b) moderate, c) many. In the absence of hippocampal tissue, patient #90015 was not studied.
  • Table 6 Immunoreactivities in the human frontal and temporal cortex and hippocampus for ⁇ amyloid precursor protein and ubiquitin-B of which the mRNA is expressed in the +1 reading frame (resulting in ⁇ APP *1 and Ubi-B +1 protein). Tissues were obtained from controls and neuropathologically confirmed Alzheimer and Down syndrome cases. Immunoreactivity present in tangles, dystrophic neurites and neuritic plaques of patients is expressed as a percentage of the total number of patients studied.
  • Controls were matched for sex, age and postmortem delay.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
EP98917502A 1997-04-10 1998-04-02 Diagnoseverfahren und reagenzien Withdrawn EP0971952A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4316397P 1997-04-10 1997-04-10
US43163P 1997-04-10
PCT/IB1998/000705 WO1998045322A2 (en) 1997-04-10 1998-04-02 Diagnosis method and reagents

Publications (1)

Publication Number Publication Date
EP0971952A2 true EP0971952A2 (de) 2000-01-19

Family

ID=21925819

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98917502A Withdrawn EP0971952A2 (de) 1997-04-10 1998-04-02 Diagnoseverfahren und reagenzien

Country Status (5)

Country Link
EP (1) EP0971952A2 (de)
JP (1) JP2001522241A (de)
AU (1) AU7071598A (de)
CA (1) CA2287084A1 (de)
WO (1) WO1998045322A2 (de)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
WO2001040804A2 (en) * 1999-12-03 2001-06-07 Koninklijke Nederlandse Akademie Van Wetenschappen Clearance of aberrant protein in correlation with disease
US7358063B2 (en) * 2001-07-19 2008-04-15 Sysmex Corporation Method of detecting PS2V
WO2004001421A2 (en) * 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
JP5116937B2 (ja) * 2003-09-16 2013-01-09 独立行政法人国立がん研究センター 哺乳動物由来の検体の癌化度を評価する方法
US7982011B2 (en) 2003-11-25 2011-07-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-cd22 antibodies and immunoconjugates
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP1916259A1 (de) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-Glycoprotein VI SCFV Fragment zur Thrombosebehandlung
EP2238170B1 (de) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antikörper gegen humanes cd39 und ihre verwendung zur hemmung der regulatorischen t-zell-aktivität
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
EP2427497B1 (de) 2009-05-07 2016-12-07 Stallergenes Verwendung von igg1-immunoglobulinen und/oder liganden des cd32-rezeptors zur behandlung entzündlicher krankheiten und ereignisse über die schleimhaut
JP2009203240A (ja) * 2009-06-15 2009-09-10 National Institute Of Advanced Industrial & Technology リポソームおよびそれからなる細胞への物質導入担体
ES2544805T3 (es) 2009-09-11 2015-09-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Exotoxina A de Pseudomonas mejorada con inmunogenicidad reducida
WO2011080322A1 (en) 2009-12-30 2011-07-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of prognosing the outcome of acquired hemophilia and of treatment of hemophilia
US9040671B2 (en) 2010-07-23 2015-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for cancer management targeting Co-029
EP2412724A1 (de) 2010-07-29 2012-02-01 Centre National de la Recherche Scientifique (C.N.R.S) Regulierung der Glypican-4-Aktivität zur Modulierung des Schicksals von Stammzellen und Verwendungen davon
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
EP2654789B1 (de) 2010-12-22 2018-05-30 Orega Biotech Antikörper gegen humanes cd39 und ihre verwendung
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
EP3147297B1 (de) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gegen icos gerichtete antikörper und verwendungen davon
SG194787A1 (en) 2011-05-06 2013-12-30 Us Gov Health & Human Serv Recombinant immunotoxin targeting mesothelin
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
KR20140033391A (ko) 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
ES2677367T3 (es) 2011-06-22 2018-08-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticuerpos anti-Axl y usos de los mismos
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
ES2636679T3 (es) 2011-06-27 2017-10-06 Université Pierre Et Marie Curie (Paris 6) Péptidos antagonistas de CCR2
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
AU2012308591B2 (en) 2011-09-16 2017-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with less immunogenic B cell epitopes
WO2014001368A1 (en) 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
AU2013204200B2 (en) * 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
HK1210713A1 (en) 2012-12-27 2016-05-06 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US10266584B2 (en) 2015-02-09 2019-04-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
US20180071413A1 (en) 2015-04-07 2018-03-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Non-invasive imaging of tumor pd-l1 expression
JP2018525029A (ja) 2015-07-07 2018-09-06 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） ミオシン１８ａに対する特異性を有する抗体およびその使用
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
MX2018010295A (es) 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
JP6899890B2 (ja) * 2016-03-18 2021-07-07 ジェンクリＧｅｎｃｌｉｓ アレルギーの分子起源
AU2017277288B2 (en) 2016-06-09 2024-05-16 Omeros Corporation Monoclonal antibodies, compositions and methods for detecting mucin -like protein (MLP) as a biomarker for ovarian and pancreatic cancer
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR101885007B1 (ko) * 2016-12-22 2018-08-31 가천대학교 산학협력단 인지기능장애의 진단 방법 및 키트
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
KR102764182B1 (ko) 2017-09-21 2025-02-07 임체크 테라퓨틱스 Ｂｔｎ２에 대해 특이성을 갖는 항체 및 이의 용도
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
JP7523358B2 (ja) * 2018-06-13 2024-07-26 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
US20220349010A1 (en) * 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
JP7652705B2 (ja) 2019-03-20 2025-03-27 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に対する特異性を有する抗体及びその使用
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
WO2021023624A1 (en) 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
EP4034560A1 (de) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müller-hemmungssubstanz-antikörper und verwendungen davon
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CA3181005A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
AU2021258464A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil
MX2022013406A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
EP4138924A1 (de) 2020-04-24 2023-03-01 Sanofi Antitumor-kombinationen mit anti-ceacam5-antikörperkonjugaten und folfiri
CA3180683A1 (en) 2020-05-12 2021-11-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
JP7634082B2 (ja) 2020-08-18 2025-02-20 オメロス コーポレーション 補体因子ｄを検出するためのモノクローナル抗体、組成物、および方法
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023006919A1 (en) 2021-07-29 2023-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) HUMANIZED ANTI-HUMAN βIG-H3 PROTEIN AND USES THEREOF
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
US20250230412A1 (en) 2022-02-01 2025-07-17 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
EP4587473A1 (de) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale Neue anti-itgb8-antikörper und ihre verwendungen
JP2026508856A (ja) 2023-03-01 2026-03-13 サノフイ Ｃｅａｃａｍ５を発現する神経内分泌がんを処置するための抗ｃｅａｃａｍ５免疫複合体の使用
EP4427763A1 (de) 2023-03-06 2024-09-11 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-vegfr-2-antikörpern und anti-pd1/pd-l1-antikörpern
KR20250169564A (ko) 2023-03-23 2025-12-03 사노피 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정
EP4713371A1 (de) 2023-05-17 2026-03-25 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d-antikörper
EP4719483A1 (de) 2023-06-05 2026-04-08 Sanofi Antitumorkombinationen mit anti-ceacam5-antikörper-wirkstoff-konjugaten, anti-pd1/pd-l1-antikörpern und anti-ctla4-antikörpern
EP4731681A1 (de) 2023-06-23 2026-04-29 Imcheck Therapeutics Bispezifische antikörper gegen btn3a und die pd-1/pd-l1-hemmende achse
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025032158A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Method to treat tauopathies
WO2025073890A1 (en) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Method to capture circulating tumor extracellular vesicles
WO2025114411A1 (en) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale New method to treat brain or neurologic disorders
TW202600175A (zh) 2024-02-15 2026-01-01 德商馬克專利公司 用於治療gd2陽性癌症之抗gd2抗體及免疫結合物
WO2025210264A1 (en) 2024-04-04 2025-10-09 Merck Patent Gmbh Antibody-drug-conjugates binding napi2b
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
EP4667490A1 (de) 2024-06-20 2025-12-24 Université de Lorraine Anti-prokollagen-antikörper und verwendungen davon
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
EP0451700A1 (de) * 1990-04-10 1991-10-16 Miles Inc. Rekombinante APP Minigene zur Expression in Transgen-Mäusen als Alzheimer-Krankheitsmuster
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
EP0786522A2 (de) * 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen
US5854392A (en) * 1992-08-31 1998-12-29 Bristol-Myers Squibb Company β APP-C100 receptor
US5449604A (en) * 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
GB9410922D0 (en) * 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9845322A2 *

Also Published As

Publication number Publication date
CA2287084A1 (en) 1998-10-15
AU7071598A (en) 1998-10-30
WO1998045322A3 (en) 1999-04-15
JP2001522241A (ja) 2001-11-13
WO1998045322A2 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
EP0971952A2 (de) Diagnoseverfahren und reagenzien
US5958684A (en) Diagnosis of neurodegenerative disease
US6620914B1 (en) Transcription factor islet-brain 1 (IB1)
JP2005218453A (ja) ８７個のヒト分泌タンパク質
JP2007524583A (ja) 自己免疫異常に関わるｈｌａ−ｄｒｍｈｃクラスｉｉ分子に関するペプチド
US6322976B1 (en) Compositions and methods of disease diagnosis and therapy
JP2018201515A (ja) Ｍｅｃｐ２ｅ１遺伝子
JPWO2001021787A1 (ja) 神経細胞死を抑制するポリペプチド、Ｈｕｍａｎｉｎ
JPH08509808A (ja) 神経糸状タンパク質遺伝子発現およびアルツハイマー病の検出
US5708156A (en) Epidermal growth factor receptor-like gene product and its uses
JP2001513777A (ja) アルツハイマー病の処置または予防のために効果的な薬物をスクリーニングするためのトランスジェニック動物および細胞株
CN101466410B (zh) 新型治疗和诊断产品及方法
US6617131B2 (en) Nucleic acid molecule encoding the potassium channel protein, KCNQ5
JP2003524366A (ja) ６４個のヒト分泌タンパク質
JP4242128B2 (ja) 脳アミロイドーシス予防・治療薬のスクリーニング方法
US7183400B1 (en) Use of ULIP proteins in the diagnosis and therapy of cancers and paraneoplastic neurological syndromes
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
US7211649B1 (en) Cartilage intermediate layer protein
JPWO2000029571A1 (ja) 新規膜貫通蛋白質をコードする遺伝子
JP2007535562A (ja) 多嚢胞性疾患の処置のための方法および組成物
JP2001501802A (ja) ハンチンチン（ｈｕｎｔｉｎｇｔｉｎ）結合蛋白質
US20030013087A1 (en) Novel mutations in the freac3 gene for diagnosis and prognosis of glaucoma and anterior segment dysgenesis
KR20010030862A (ko) 프리세닐린과 상호작용할 수 있는 단백질을 암호화하는 핵산
JP2002517998A (ja) ｐ２７（ＫＩＰ１）のＦＫＢＰ−１２との相互作用
JP2004057180A (ja) 変異アンドロゲン受容体、それを発現する癌細胞、それらの作出方法およびそれらの用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19991019;LT PAYMENT 19991019;LV PAYMENT 19991019;MK PAYMENT 19991019;RO PAYMENT 19991019;SI PAYMENT 19991019

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031101